



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/80, 15/60, 9/88, 1/14 // (C12N 1/14, C12R 1:77)	A2	(11) International Publication Number: WO 00/42203 (43) International Publication Date: 20 July 2000 (20.07.00)
(21) International Application Number: PCT/US00/00913 (22) International Filing Date: 13 January 2000 (13.01.00) (30) Priority Data: 09/229,862 13 January 1999 (13.01.99) US (71) Applicant (for all designated States except US): NOVO NORDISK BIOTECH, INC. [US/US]; 1445 Drew Avenue, Davis, CA 95616 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BERKA, Randy, M. [-/US]; 3609 Modoc, Davis, CA 95616 (US). REY, Michael, W. [-/US]; 605 Robin Place, Davis, CA 95616 (US). YODER, Wendy, T. [-/US]; 8503 Pleasants Valley Road, Winters, CA 95694 (US). (74) Agents: ZELSON, Steve, T. et al.; Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHODS FOR PRODUCING POLYPEPTIDES IN CYCLOHEXADEPSIPEPTIDE-DEFICIENT CELLS (57) Abstract <p>The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wherein (i) the mutant cell comprises a nucleic acid sequence encoding the heterologous polypeptide and (ii) the mutant produces less of the cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under the same conditions; and (b) isolating the heterologous polypeptide from the cultivation medium. The present invention also relates to mutants of filamentous fungal cells and methods for obtaining the mutant cells. The present invention also relates to isolated cyclohexadepsipeptide synthetases and isolated nucleic acid sequences encoding the cyclohexadepsipeptide synthetases. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the cyclohexadepsipeptide synthetases. The present invention further relates to cyclohexadepsipeptides produced by the cyclohexadepsipeptide synthetases.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHODS FOR PRODUCING POLYPEPTIDES IN CYCLOHEXADEPSIPEPTIDE-DEFICIENT CELLS

5

Background of the Invention

Field of the Invention

The present invention relates to methods for producing heterologous polypeptides in cyclohexadepsipeptide-deficient filamentous fungal mutant cells. The present
10 invention also relates to mutants of filamentous fungal cells and methods for obtaining the mutant cells. The present invention also relates to isolated cyclohexadepsipeptide synthetases and isolated nucleic acid sequences encoding the cyclohexadepsipeptide synthetases. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the
15 cyclohexadepsipeptide synthetases. The present invention further relates to cyclohexadepsipeptides produced by the cyclohexadepsipeptide synthetases.

Description of the Related Art

Depsipeptides constitute a large class of peptide-related compounds derived from
20 hydroxy and amino acids joined by amide and ester linkages. Many members of this class of compounds are biologically active and include antibiotics, alkaloids, and proteins (Shemyakin *et al.*, 1969, *Journal of Membrane Biology* 1: 402-430). Examples include the enniatins, beauvericin, and bassianolide.

Enniatins are cyclohexadepsipeptide phytoxins with ionophoretic properties
25 produced by various species of actinomycetes and filamentous fungi, particularly strains of *Fusarium*. They are composed of alternating D-2-hydroxyisovaleric acid residues and L-amino acids or N-methyl-L-amino acids to form an 18-membered cyclic structure and may contain more than one species of amino acid.

The biosynthesis of enniatins is catalyzed by enniatin synthetase, which is a large
30 multifunctional enzyme that has all the essential functions for assembling enniatins from their primary precursors, *i.e.*, D-2-hydroxyisovaleric acid, a branched chain L-amino acid (*e.g.*, valine, leucine, isoleucine), S-adenosylmethionine, and ATP (Reper *et al.*, 1995, *European Journal of Biochemistry* 230: 119-126). The precursors (D-2-

hydroxyisovaleric acid and branched chain L-amino acid) are activated as thioesters. Covalently bound substrate amino acid residues are methylated under the consumption of S-adenosylmethionine. Then peptide bond formation and cyclization reactions occur.

Enniatins are postulated to play a role in wilt toxic events during infection by enniatin-producing fusaria (Walton, 1990, *Biochemistry of Peptide Antibiotics*, H. Kleinkauf and H. von Dohren, editors, W. de Gruyter, Berlin, pp. 179-203), and also exhibit entomopathogenic properties (Grove and Pople, 1980, *Mycopathologia* 70: 103-105).

The enniatin synthetase gene (*esyn1*) has been cloned from *Fusarium scirpi* (Haese *et al.*, 1993, *Molecular Microbiology* 7: 905-914).

Enniatin synthetase mutants of *Fusarium avenaceum* have been generated that do not produce enniatins (Herrmann *et al.*, 1996, *Molecular Plant-Microbe Interactions* 9: 226-232).

It is an object of the present invention to provide methods for producing heterologous polypeptides in cyclohexadepsipeptide-deficient filamentous fungal mutant cells.

Summary of the Invention

The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wherein (i) the mutant cell comprises a first nucleic acid sequence encoding the heterologous polypeptide, and (ii) the mutant produces less of a cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under the same conditions; and (b) isolating the heterologous polypeptide from the cultivation medium.

The present invention also relates to mutants of filamentous fungal cells and methods for obtaining the mutant cells.

The present invention also relates to isolated cyclohexadepsipeptide synthetases from *Fusarium venenatum* and isolated nucleic acid sequences encoding the cyclohexadepsipeptide synthetases. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for

producing the cyclohexadepsipeptide synthetases.

The present invention further relates to cyclohexadepsipeptides produced by the cyclohexadepsipeptide synthetases.

5

Brief Description of Figure

Figure 1 shows the genomic nucleic acid sequence and the deduced amino acid sequence of a *Fusarium venenatum* ATCC 20334 cyclohexadepsipeptide synthetase (SEQ ID NOS: 1 and 2, respectively).

10

Figure 2 shows the construction of pAES-*amdS*.

Detailed Description of the Invention

The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wherein (i) the mutant filamentous fungal cell comprises a first nucleic acid sequence encoding the heterologous polypeptide and (ii) the mutant produces less of a cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under the same conditions; and (b) isolating the heterologous polypeptide from the cultivation medium of the mutant cell.

The term "cyclohexadepsipeptide" is defined herein as a family of peptide-related compounds composed of hydroxy and amino acids linked by amide and ester bonds.

The term "production of a cyclohexadepsipeptide" is defined herein as to include any step involved in the production of a cyclohexadepsipeptide including, but not limited to, biosynthesis, regulation of biosynthesis, transport, and secretion.

In a preferred embodiment, the cyclohexadepsipeptide is an enniatin.

The term "enniatins" is defined herein as a family of cyclohexadepsipeptides composed of three D-2-hydroxyisovaleric acid residues joined alternatively to L-amino acids or N-methyl-L-amino acids to produce an 18-membered cyclic structure. The enniatins include, but are not limited to, enniatin A, A₁, B, B₁, B₂, B₃, B₄, C, D, E, and F; and derivatives thereof (Visconte *et al.*, 1992, *Journal of Agricultural and Food*

Chemistry 40: 1076-1082; Tomodo *et al.*, 1992, *Journal of Antibiotics* 45: 1207-1215), and mixed-type enniatins containing more than one species of amino acid (Zocher *et al.* 1982, *Biochemistry* 21: 43-48).

In the methods of the present invention, the filamentous fungal cell may be a
5 wild-type cell or a mutant thereof. Furthermore, the filamentous fungal cell may be a cell that does not produce any detectable cyclohexadepsipeptide(s), but contains the genes encoding the cyclohexadepsipeptide(s). Preferably, the filamentous fungal cell is an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Beauveria*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Gibberella*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Myrothecium*,
10 *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Polyporus*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

In a preferred embodiment, the filamentous fungal cell is an *Aspergillus*
aculeatus, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus*
15 *nidulans*, *Aspergillus niger*, or *Aspergillus oryzae* cell.

In another preferred embodiment, the filamentous fungal cell is a *Fusarium*
acuminatum, *Fusarium avenaceum*, *Fusarium bactridioides*, *Fusarium compactum*,
Fusarium crookwellense (synonym of *Fusarium cerealis*), *Fusarium culmorum*,
Fusarium equiseti, *Fusarium gibbosum*, *Fusarium graminearum*, *Fusarium graminum*,
20 *Fusarium heterosporum*, *Fusarium lateritium*, *Fusarium moniliforme*, *Fusarium*
negundi, *Fusarium nivale*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium*
roseum, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium scirpi*, *Fusarium*
semitectum, *Fusarium solani*, *Fusarium sporotrichioides*, *Fusarium sulphureum*,
Fusarium torulosum, *Fusarium trichothecioides*, *Fusarium tricinctum*, or *Fusarium*
25 *venenatum* cell.

In another preferred embodiment, the filamentous fungal cell is a *Gibberella*
pulicaris, *Gibberella zeae*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*,
Myceliophthora thermophila, *Myrothecium roridin*, *Neurospora crassa*, *Paecilomyces*
fumoso-roseus, *Penicillium purpurogenum*, or *Polyporus sulphureus* cell.

30 In another preferred embodiment, the filamentous fungal cell is a *Trichoderma*
harzianum, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or
Trichoderma viride cell.

In a more preferred embodiment, the *Fusarium venenatum* cell is *Fusarium venenatum* A3/5, which was originally deposited as *Fusarium graminearum* ATCC 20334 and recently reclassified as *Fusarium venenatum* by Yoder and Christianson, 1998, *Fungal Genetics and Biology* 23: 62-80 and O'Donnell *et al.*, 1998, *Fungal Genetics and Biology* 23: 57-67; as well as taxonomic equivalents of *Fusarium venenatum* regardless of the species name by which they are currently known. In another more preferred embodiment, the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* A3/5 or *Fusarium venenatum* ATCC 20334, as disclosed in WO 97/26330.

10 The filamentous fungal cell may also be a cell involved in the production of products containing (parts of) the mycelium, for example, in the production of the product QUORN™ (Marlow Foods, Ltd., Great Britain), which is produced from a *Fusarium* strain.

In the methods of the present invention, the mutant cell comprises a second
15 nucleic acid sequence which comprises a modification of at least one of the genes involved in the production of the cyclohexadepsipeptide. Any gene of a filamentous fungal cell involved in the production of a cyclohexadepsipeptide may be modified. In a preferred embodiment, the gene is a cyclohexadepsipeptide synthetase gene. In a more preferred embodiment, the gene is an enniatin synthetase gene. In another more preferred
20 embodiment, the gene is a D-hydroxyisovalerate dehydrogenase gene. D-Hydroxyisovalerate dehydrogenase catalyzes the conversion of 2-ketoisovalerate to D-hydroxyisovalerate (Lee and Zocher, 1996, *Journal of Biochemistry and Molecular Biology* 29: 493-499). In an even more preferred embodiment, the gene is a *Fusarium venenatum* cyclohexadepsipeptide synthetase gene having (a) a nucleic acid sequence
25 encoding a polypeptide having an amino acid sequence which has at least 65% identity with the mature polypeptide contained within SEQ ID NO:2; (b) a nucleic acid sequence having at least 65% homology with the mature polypeptide coding region of SEQ ID NO:1; (c) a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID
30 NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii); (d) an allelic variant of (a), (b), or (c); or (e) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide fragment which has

cyclohexadepsipeptide synthetase activity. In a most preferred embodiment, the gene is a *Fusarium venenatum* cyclohexadepsipeptide synthetase gene having the nucleic acid sequence of SEQ ID NO:1.

5 The cyclohexadepsipeptide-deficient filamentous fungal mutant cell may be constructed by reducing or eliminating expression of one or more of the genes described above using methods well known in the art, for example, insertions, disruptions, replacements, or deletions. The gene to be modified or inactivated may be, for example, the coding region or a part thereof essential for activity, or a regulatory element of the gene required for the expression of the coding region. An example of such a regulatory
10 or control sequence may be a promoter sequence or a functional part thereof, *i.e.*, a part that is sufficient for affecting expression of the nucleic acid sequence. Other control sequences for possible modification include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, signal peptide sequence, transcription terminator, and transcriptional activator.

15 Modification or inactivation of the gene may be performed by subjecting the parent cell to mutagenesis and selecting for mutant cells in which expression of the gene has been reduced or eliminated. The mutagenesis, which may be specific or random, may be performed, for example, by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR
20 generated mutagenesis. Furthermore, the mutagenesis may be performed by use of any combination of these mutagenizing agents.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane
25 sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically performed by incubating the parent cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and screening and/or selecting for mutant cells exhibiting reduced or no expression of the gene.

30 Modification or inactivation of the gene may be accomplished by introduction, substitution, or removal of one or more nucleotides in the gene or a regulatory element required for the transcription or translation thereof. For example, nucleotides may be

inserted or removed so as to result in the introduction of a stop codon, the removal of the start codon, or a change in the open reading frame. Such modification or inactivation may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art. Although, in principle, the modification may
5 be performed *in vivo*, i.e., directly on the cell expressing the gene to be modified, it is preferred that the modification be performed *in vitro* as exemplified below.

An example of a convenient way to eliminate or reduce production of a cyclohexadepsipeptide by a filamentous fungal cell of choice is based on techniques of gene replacement, gene deletion, or gene disruption. For example, in the gene disruption
10 method, a nucleic acid sequence corresponding to the endogenous gene or gene fragment of interest is mutagenized *in vitro* to produce a defective nucleic acid sequence which is then transformed into the parent cell to produce a defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous gene or gene fragment. It may be desirable that the defective gene or gene fragment also encodes a
15 marker that may be used for selection of transformants in which the nucleic acid sequence has been modified or destroyed. In a particularly preferred embodiment, the gene is disrupted with a selectable marker such as those described herein.

Alternatively, modification or inactivation of the gene may be performed by established anti-sense techniques using a nucleotide sequence complementary to the
20 nucleic acid sequence of the gene. More specifically, expression of the gene by a filamentous fungal cell may be reduced or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence of the gene that may be transcribed in the cell and is capable of hybridizing to the mRNA produced in the cell. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to
25 the mRNA, the amount of protein translated is thus reduced or eliminated.

A nucleic acid sequence complementary or homologous to the nucleic acid sequence of a gene involved in the production of a cyclohexadepsipeptide may be obtained from other microbial sources that produce cyclohexadepsipeptides.

Preferred sources for an enniatin synthetase gene having a nucleic acid sequence
30 complementary or homologous to the nucleic acid sequence of SEQ ID NO:1 of *Fusarium venenatum* include other *Fusarium* strains. A more preferred source is *Fusarium scirpi* (Haese *et al.*, 1993, *supra*).

Preferred sources for D-hydroxyisovalerate dehydrogenase genes that may be complementary or homologous to the nucleic acid sequence of the corresponding genes of a filamentous fungal cell include other *Fusarium* strains. A more preferred source for the D-hydroxyisovalerate dehydrogenase gene is *Fusarium sambucinum* (Lee and Zocher, 1996, *supra*). Furthermore, the nucleic acid sequences may be native to the filamentous fungal cell.

The level of cyclohexadepsipeptides produced by a mutant filamentous fungal cell of the present invention may be determined using the method of Visconti *et al.*, 1992, *Journal of Agriculture and Food Chemistry* 40: 1076-1082. Specifically, one ml of *Fusarium venenatum* cell-free culture broth is extracted twice with 2.0 ml ethyl acetate. The combined organic extracts are evaporated to dryness under a stream of nitrogen gas and redissolved in 0.5 ml hexane. One microliter samples are analyzed using a Hewlett-Packard 6890 GC/Series MSD system operating in the electron impact (EI) mode. Samples are injected on-column and separated utilizing a DB-5 capillary column (30 m x 0.25 mm, 0.25 μ m film) employing a temperature program with heating from 120 to 300°C at a rate of 15°C/min. For example, enniatins A, A1, B, B1, B2 and B3 are identified by *m/z* ratios for the ($M^+ + H$) ion of 682, 668, 640, 654, 626 and 612, respectively.

The mutant filamentous fungal cell preferably produces at least about 25% less, more preferably at least about 50% less, even more preferably at least about 75% less, most preferably at least about 95% less, and even most preferably no cyclohexadepsipeptide than the corresponding parent filamentous fungal cell when cultured under identical conditions. The parent and mutant cells may be compared with regard to production of a cyclohexadepsipeptide under conditions conducive for the production of a polypeptide of interest or under conditions conducive for the production of a cyclohexadepsipeptide.

In another aspect of the present invention, the mutant filamentous fungal cell may additionally contain modifications of one or more third nucleic acid sequences that encode proteins that may be detrimental to the production, recovery, and/or application of the heterologous polypeptide of interest. The modification reduces or eliminates expression of the one or more third nucleic acid sequences resulting in a mutant cell that may produce more of the heterologous polypeptide than the mutant cell without the

modification of the third nucleic acid sequence when cultured under the same conditions.

The third nucleic acid sequence may encode any protein or enzyme. For example, the enzyme may be an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, 5 esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase. The third nucleic acid sequence preferably encodes a proteolytic enzyme, *e.g.*, an aminopeptidase, carboxypeptidase, or 10 endoprotease.

The mutant filamentous fungal cell is cultivated in a nutrient medium suitable for production of a heterologous polypeptide of interest using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in 15 laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the heterologous polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in 20 catalogues of the American Type Culture Collection). The secreted heterologous polypeptide can be recovered directly from the medium.

The heterologous polypeptide may be detected using methods known in the art that are specific for the polypeptide. These detection methods may include use of specific antibodies, formation of an enzyme product, disappearance of an enzyme 25 substrate, or SDS-PAGE. For example, an enzyme assay may be used to determine the activity of the heterologous polypeptide. Procedures for determining enzyme activity are known in the art for many enzymes.

The resulting heterologous polypeptide may be isolated by methods known in the art. For example, the polypeptide may be isolated from the nutrient medium by 30 conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The isolated polypeptide may then be further purified by a variety of procedures known in the art including, but not

limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 5 1989).

The polypeptide may be any polypeptide heterologous to the mutant filamentous fungal cell. The term "polypeptide" is not meant herein to refer to a specific length of the encoded product and, therefore, encompasses peptides, oligopeptides, and proteins. The term "heterologous polypeptide" is defined herein as a polypeptide that is not native to 10 the fungal cell, a native protein in which modifications have been made to alter the native sequence, or a native protein whose expression is quantitatively altered as a result of a manipulation of the fungal cell by recombinant DNA techniques. The mutant fungal cell may contain one or more copies of the nucleic acid sequence encoding the polypeptide. In a preferred embodiment, the heterologous polypeptide is an extracellularly secreted 15 polypeptide.

Preferably, the heterologous polypeptide is a hormone, hormone variant, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter. In a more preferred embodiment, the heterologous polypeptide is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase. In an even more preferred embodiment, the heterologous 20 polypeptide is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, polyphenoloxidase, proteolytic enzyme, 25 ribonuclease, transglutaminase or xylanase.

The nucleic acid sequence encoding a heterologous polypeptide that can be expressed in a filamentous fungal cell may be obtained from any prokaryotic, eukaryotic, or other source. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide is produced by 30 the source or by a cell in which a gene from the source has been inserted.

In the methods of the present invention, the mutant filamentous fungal cell may also be used for the recombinant production of polypeptides that are native to the cell.

The native polypeptides may be recombinantly produced by, *e.g.*, placing a gene encoding the polypeptide under the control of a different promoter to enhance expression of the polypeptide, to expedite export of a native polypeptide of interest outside the cell by use of a signal sequence, and to increase the copy number of a gene encoding the polypeptide normally produced by the cell. The present invention also encompasses, within the scope of the term "heterologous polypeptide", such recombinant production of homologous polypeptides, to the extent that such expression involves the use of genetic elements not native to the cell, or use of native elements that have been manipulated to function in a manner that do not normally occur in the host cell.

The techniques used to isolate or clone a nucleic acid sequence encoding a heterologous polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequence from such genomic DNA can be effected, *e.g.*, by using the well known polymerase chain reaction (PCR). See, for example, Innis *et al.*, 1990, *PCR Protocols: A Guide to Methods and Application*, Academic Press, New York. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into the mutant fungal cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

In the methods of the present invention, heterologous polypeptides may also include fused or hybrid polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding one polypeptide to a nucleic acid sequence (or a portion thereof) encoding another polypeptide. Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and expression of the fused polypeptide is under control of the same promoter(s) and terminator. The hybrid polypeptides may comprise a combination of partial or complete polypeptide sequences obtained from at least two different polypeptides wherein one or more may be heterologous to the mutant filamentous fungal cell.

An isolated nucleic acid sequence encoding a heterologous polypeptide of interest may be manipulated in a variety of ways to provide for expression of the polypeptide. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, isolated from a naturally occurring gene or modified to contain segments of nucleic acid that are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence. The term "coding sequence" as defined herein is a sequence that is transcribed into mRNA and translated into a polypeptide. The boundaries of the coding sequence are generally determined by the ATG start codon located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, genomic, cDNA, RNA, semisynthetic, synthetic, recombinant, or any combinations thereof.

The term "control sequences" is defined herein to include all components that are necessary or advantageous for the expression of a heterologous polypeptide. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a heterologous polypeptide. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to

the coding sequence of the DNA sequence such that the control sequence directs the production of a heterologous polypeptide.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence that is recognized by a filamentous fungal cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences that mediate the expression of the heterologous polypeptide. The promoter may be any nucleic acid sequence that shows transcriptional activity in the filamentous fungal cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs in the methods of the present invention are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Aspergillus oryzae* acetamidase (*amdS*), *Fusarium oxysporum* trypsin-like protease (U.S. Patent No. 4,288,627), and mutant, truncated, and hybrid promoters thereof. Particularly preferred promoters are the NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), glucoamylase, and TAKA amylase promoters.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a filamentous fungal cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the heterologous polypeptide. Any terminator that is functional in the filamentous fungal cell may be used in the present invention.

Preferred terminators are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthetase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

The control sequence may also be a suitable leader sequence, a nontranslated

region of a mRNA that is important for translation by the filamentous fungal cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the heterologous polypeptide. Any leader sequence that is functional in the filamentous fungal cell may be used in the present invention.

5 Preferred leaders are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleic acid sequence and, when transcribed, is recognized by a filamentous fungal cell as a signal to add polyadenosine residues to
10 transcribed mRNA. Any polyadenylation sequence that is functional in the filamentous fungal cell may be used in the present invention.

Preferred polyadenylation sequences are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, and *Aspergillus niger* alpha-glucosidase.

15 The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of the heterologous polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the
20 coding region that encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region that is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding
25 region in order to enhance secretion of the polypeptide. The signal peptide coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, or a lipase or proteinase gene from a *Rhizomucor* species. However, any signal peptide coding region that directs the expressed heterologous polypeptide into the secretory pathway of a filamentous fungal cell may be used in the present invention.

30 An effective signal peptide coding region is the signal peptide coding region obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, *Rhizomucor miehei* aspartic proteinase gene, and *Humicola lanuginosa*

cellulase.

The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases).

5 A propolypeptide is generally inactive and can be converted to a mature, active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes encoding *Rhizomucor miehei* aspartic proteinase and *Myceliophthora thermophila* laccase (WO 95/33836).

10 Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of the polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

The nucleic acid constructs may also comprise one or more nucleic acid
15 sequences that encode one or more factors that are advantageous for directing the expression of the heterologous polypeptide, *e.g.*, a transcriptional activator (*e.g.*, a *trans*-acting factor), chaperone, and processing protease. Any factor that is functional in a filamentous fungal cell may be used in the present invention. The nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence
20 encoding the heterologous polypeptide.

It may also be desirable to add regulatory sequences that allow the regulation of the expression of the heterologous polypeptide relative to the growth of the filamentous fungal cell. Examples of regulatory systems are those that cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the
25 presence of a regulatory compound. The TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those that allow for gene amplification, *e.g.*, the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the heterologous
30 polypeptide would be operably linked with the regulatory sequence.

The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector that may include one or more

convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the heterologous polypeptide at such sites. Alternatively, the nucleic acid sequence encoding the heterologous polypeptide may be expressed by inserting the sequence or a nucleic acid construct comprising the sequence into an appropriate vector
5 for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can bring about
10 the expression of the nucleic acid sequence encoding the heterologous polypeptide. The choice of the vector will typically depend on the compatibility of the vector with the filamentous fungal cell into which the vector is to be introduced. The vector may be a linear or closed circular plasmid. The vector may be an autonomously replicating vector, *i.e.*, a vector that exists as an extrachromosomal entity, the replication of which is
15 independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one that, when introduced into the filamentous fungal cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single
20 vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the filamentous fungal cell, or a transposon.

The vector preferably contains one or more selectable markers that permit easy selection of transformed filamentous fungal cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals,
25 prototrophy to auxotrophs, and the like. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), and *trpC*
30 (anthranilate synthase), as well as equivalents thereof. Preferred for use in a filamentous fungal cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygrosopicus*.

The vector preferably contains an element(s) that permits stable integration of the vector into a filamentous fungal cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

5 "Introduction" means introducing a vector comprising the nucleic acid sequence into a filamentous fungal cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the chromosome occurs by homologous recombination, non-homologous recombination, or transposition.

10 The introduction of an expression vector into a filamentous fungal cell may involve a process consisting of protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. A suitable
15 method of transforming *Fusarium* species is described by Malardier *et al.*, 1989, *Gene* 78: 147-156 or in WO 96/00787.

For integration into the genome of a filamentous fungal cell, the vector may rely on the nucleic acid sequence encoding the heterologous polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or
20 nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the filamentous fungal cell. The additional nucleic acid sequences enable the vector to be integrated into the genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should
25 preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequences that are homologous with the target sequence in the genome of the filamentous fungal cell.
30 Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the filamentous fungal cell in question.

It will be understood that the methods of the present invention are not limited to a particular order for obtaining the mutant filamentous fungal cell. The modification of a gene involved in the production of a cyclohexadepsipeptide may be introduced into the parent cell at any step in the construction of the cell for the production of a heterologous polypeptide. It is preferable that the filamentous fungal mutant has already been made cyclohexadepsipeptide-deficient using the methods of the present invention prior to the introduction of a gene encoding a heterologous polypeptide.

The procedures used to ligate the elements described herein to construct the recombinant expression vectors are well known to one skilled in the art (see, e.g., J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York).

The present invention also relates to methods for obtaining cyclohexadepsipeptide-deficient filamentous fungal mutant cells which comprise (a) introducing into a parent filamentous fungal cell a first nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a cyclohexadepsipeptide and a second nucleic acid sequence encoding a heterologous polypeptide; and (b) identifying the mutant from step (a) comprising the modified nucleic acid sequence, wherein the mutant cell produces less of the cyclohexadepsipeptide than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.

The present invention also relates to cyclohexadepsipeptide-deficient mutants of filamentous fungal cells for producing a heterologous polypeptide which comprise a first nucleic acid sequence comprising a modification of at least one of the genes involved in the production of a cyclohexadepsipeptide and a second nucleic acid sequence encoding the heterologous polypeptide, wherein the mutant produces less of the cyclohexadepsipeptide than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.

The present invention also relates to isolated cyclohexadepsipeptide synthetases. The term "cyclohexadepsipeptide synthetase activity" is defined herein as a synthetase

activity which catalyzes the production of a cyclohexadepsipeptide from D-2-hydroxyisovaleric acid, a branched chain L-amino acid (e.g., valine, leucine, isoleucine), S-adenosylmethionine, and ATP. For purposes of the present invention, cyclohexadepsipeptide synthetase activity is determined by measuring the production of a cyclohexadepsipeptide according to the procedure of Zocher *et al.*, 1982, *Biochemistry* 21: 43-48. Specifically, the cyclohexadepsipeptide synthetase is incubated with 1 mM valine, 0.2 mM S-adenosylmethionine, 0.2 mM D-2-hydroxyisovaleric acid, 4 mM ATP, and 4 mM Mg(OAc)₂ in a total volume of 100 µl for 10 minutes at 37°C in 50 mM MOPS pH 7.0. The amount of cyclohexadepsipeptide is determined as described herein based on the method of Visconti *et al.*, 1992, *supra*. One unit of cyclohexadepsipeptide synthetase activity is defined as 1.0 µmole of cyclohexadepsipeptide produced per minute at 37°C, pH 7.0.

In a first embodiment, the present invention relates to isolated cyclohexadepsipeptide synthetases having an amino acid sequence which has a degree of identity to the mature polypeptide contained within SEQ ID NO:2 of at least about 65%, preferably at least about 70%, more preferably at least about 80%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97%, which have cyclohexadepsipeptide synthetase activity (hereinafter "homologous cyclohexadepsipeptide synthetases"). In a preferred embodiment, the homologous cyclohexadepsipeptide synthetases have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from the mature polypeptide contained within SEQ ID NO:2. For purposes of the present invention, the degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™ MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10, and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

Preferably, the cyclohexadepsipeptide synthetases of the present invention comprise the amino acid sequence of SEQ ID NO:2 or an allelic variant thereof; or a fragment thereof that has cyclohexadepsipeptide synthetase activity. In a more preferred

embodiment, the cyclohexadepsipeptide synthetase of the present invention comprises the amino acid sequence of SEQ ID NO:2. In another preferred embodiment, the cyclohexadepsipeptide synthetase of the present invention comprises the mature polypeptide contained within SEQ ID NO:2, or an allelic variant thereof; or a fragment thereof that has cyclohexadepsipeptide synthetase activity. In another preferred embodiment, the cyclohexadepsipeptide synthetase of the present invention comprises the mature polypeptide contained within SEQ ID NO:2. In another preferred embodiment, the cyclohexadepsipeptide synthetase of the present invention consists of the amino acid sequence of SEQ ID NO:2 or an allelic variant thereof; or a fragment thereof that has cyclohexadepsipeptide synthetase activity. In another preferred embodiment, the cyclohexadepsipeptide synthetase of the present invention consists of the amino acid sequence of SEQ ID NO:2. In another preferred embodiment, the cyclohexadepsipeptide synthetase consists of the mature polypeptide contained within SEQ ID NO:2 or an allelic variant thereof; or a fragment thereof that has cyclohexadepsipeptide synthetase activity. In another preferred embodiment, the cyclohexadepsipeptide synthetase consists of the mature polypeptide contained within SEQ ID NO:2.

A fragment of SEQ ID NO:2 is a polypeptide having one or more amino acids deleted from the amino and/or carboxyl terminus of this amino acid sequence. Preferably, a fragment contains at least 2854 amino acid residues, more preferably at least 2954 amino acid residues, and most preferably at least 3054 amino acid residues.

An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

The amino acid sequences of the homologous cyclohexadepsipeptide synthetases may differ from the amino acid sequence of SEQ ID NO:2 or the mature polypeptide thereof by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid

substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by
5 changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine,
10 isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions that do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile,
15 Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

In a second embodiment, the present invention relates to isolated cyclohexadepsipeptide synthetases encoded by nucleic acid sequences that hybridize under low stringency conditions, more preferably medium stringency conditions, even
20 more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleic acid probe that hybridizes under the same conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii) (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory*
25 *Manual*, 2d edition, Cold Spring Harbor, New York). The subsequence of SEQ ID NO:1 may be at least 100 nucleotides or preferably at least 200 nucleotides. Moreover, the subsequence may encode a polypeptide fragment that has cyclohexadepsipeptide synthetase activity. The cyclohexadepsipeptide synthetases may also be allelic variants or fragments that have cyclohexadepsipeptide synthetase activity.

30 The nucleic acid sequence of SEQ ID NO:1 or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO:2 or a fragment thereof, may be used to design a nucleic acid probe to identify and clone DNA encoding cyclohexadepsipeptide

synthetases from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes
5 can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 35 nucleotides in length. Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin). Such probes are encompassed by the present invention.

10 Thus, a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA that hybridizes with the probes described above and encodes a cyclohexadepsipeptide synthetase. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and
15 immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA that is homologous with SEQ ID NO:1 or a subsequence thereof, the carrier material is used in a Southern blot. For purposes of the present invention, hybridization indicates that the nucleic acid sequence hybridizes to a nucleic acid probe corresponding to (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence
20 of SEQ ID NO:1, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii) under low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions are detected using X-ray film.

In a preferred embodiment, the nucleic acid probe is a nucleic acid sequence that encodes the cyclohexadepsipeptide synthetase of SEQ ID NO:2, or a subsequence
25 thereof. In another preferred embodiment, the nucleic acid probe is SEQ ID NO:1. In another preferred embodiment, the nucleic acid probe is the mature polypeptide coding region contained within SEQ ID NO:1. In another preferred embodiment, the nucleic acid probe is the nucleic acid sequences contained in plasmid pZL-ESA, which is contained in *Escherichia coli* NRRL B-30068, plasmid pZL-ESB, which is contained in
30 *Escherichia coli* NRRL B-30069, and plasmid pZL-ESC, which is contained in *Escherichia coli* NRRL B-30070, wherein the nucleic acid sequences encode the cyclohexadepsipeptide synthetase of SEQ ID NO:2. In another preferred embodiment,

the nucleic acid probe is the nucleic acid sequence encoding the mature cyclohexadepsipeptide synthetase of SEQ ID NO:2 contained in plasmid pZL-ESA, which is contained in *Escherichia coli* NRRL B-30068, plasmid pZL-ESB, which is contained in *Escherichia coli* NRRL B-30069, and plasmid pZL-ESC, which is contained
5 in *Escherichia coli* NRRL B-30070.

For long probes of at least 100 nucleotides in length, low to very high stringency conditions are defined as prehybridization and hybridization at 45°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high
10 stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures.

For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.2% SDS preferably at least at 45°C (very low stringency), more preferably at least at 50°C (low stringency), more
15 preferably at least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), even more preferably at least at 65°C (high stringency), and most preferably at least at 70°C (very high stringency).

For short probes that are about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-
20 hybridization at 5°C to 10°C below the calculated T_m using the calculation according to Bolton and McCarthy (1962, *Proceedings of the National Academy of Sciences USA* 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting
25 procedures.

For short probes that are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T_m .

In a third embodiment, the present invention relates to isolated polypeptides
30 having immunochemical identity or partial immunochemical identity to the cyclohexadepsipeptide synthetase having the amino acid sequence of SEQ ID NO:2 or the mature polypeptide thereof. The immunochemical properties are determined by

immunological cross-reaction identity tests by the well-known Ouchterlony double immunodiffusion procedure. Specifically, an antiserum containing polyclonal antibodies that are immunoreactive or bind to epitopes of the polypeptide having the amino acid sequence of SEQ ID NO:2 or the mature polypeptide thereof are prepared by immunizing
5 rabbits (or other rodents) according to the procedure described by Harboe and Ingild, In N.H. Axelsen, J. Krøll, and B. Weeks, editors, *A Manual of Quantitative Immunelectrophoresis*, Blackwell Scientific Publications, 1973, Chapter 23, or Johnstone and Thorpe, *Immunochemistry in Practice*, Blackwell Scientific Publications, 1982 (more specifically pages 27-31). A polypeptide having immunochemical identity is
10 a polypeptide that reacts with the antiserum in an identical fashion such as total fusion of precipitates, identical precipitate morphology, and/or identical electrophoretic mobility using a specific immunochemical technique. A further explanation of immunochemical identity is described by Axelsen, Bock, and Krøll, In N.H. Axelsen, J. Krøll, and B. Weeks, editors, *A Manual of Quantitative Immunelectrophoresis*, Blackwell Scientific
15 Publications, 1973, Chapter 10. A polypeptide having partial immunochemical identity is a polypeptide that reacts with the antiserum in a partially identical fashion such as partial fusion of precipitates, partially identical precipitate morphology, and/or partially identical electrophoretic mobility using a specific immunochemical technique. A further explanation of partial immunochemical identity is described by Bock and Axelsen, In
20 N.H. Axelsen, J. Krøll, and B. Weeks, editors, *A Manual of Quantitative Immunelectrophoresis*, Blackwell Scientific Publications, 1973, Chapter 11.

The antibody may also be a monoclonal antibody. Monoclonal antibodies may be prepared and used, e.g., according to the methods of E. Harlow and D. Lane, editors, 1988, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor,
25 New York.

The isolated cyclohexadepsipeptide synthetases of the present invention have at least 20%, preferably at least 40%, more preferably at least 60%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 100% of the cyclohexadepsipeptide synthetase activity of the mature polypeptide of SEQ ID NO:2.

30 In a preferred embodiment, a cyclohexadepsipeptide synthetase of the present invention is obtained from a *Fusarium venenatum* strain, and more preferably from *Fusarium venenatum* ATCC 20334 or a mutant strain thereof, e.g., the polypeptide with

the amino acid sequence of SEQ ID NO:2.

As defined herein, an "isolated" cyclohexadepsipeptide synthetase is a polypeptide that is essentially free of other polypeptides, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more
5 preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

A cyclohexadepsipeptide synthetase of the present invention may be obtained from microorganisms of any genus.

A cyclohexadepsipeptide synthetase of the present invention may be a bacterial
10 cyclohexadepsipeptide synthetase. For example, the cyclohexadepsipeptide synthetase may be a gram positive bacterial cyclohexadepsipeptide synthetase such as a *Bacillus* cyclohexadepsipeptide synthetase, *e.g.*, a *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus*
15 *stearothermophilus*, *Bacillus subtilis*, or *Bacillus thuringiensis* cyclohexadepsipeptide synthetase; or a *Streptomyces* cyclohexadepsipeptide synthetase, *e.g.*, a *Streptomyces lividans* or *Streptomyces murinus* cyclohexadepsipeptide synthetase; or a gram negative bacterial cyclohexadepsipeptide synthetase, *e.g.*, an *E. coli* or a *Pseudomonas* sp. cyclohexadepsipeptide synthetase.

20 A cyclohexadepsipeptide synthetase of the present invention may be a fungal cyclohexadepsipeptide synthetase, and more preferably a yeast cyclohexadepsipeptide synthetase such as a *Candida*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cyclohexadepsipeptide synthetase; or more preferably a filamentous fungal cyclohexadepsipeptide synthetase such as an *Acremonium*,
25 *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cyclohexadepsipeptide synthetase.

In a preferred embodiment, the cyclohexadepsipeptide synthetase is a
30 *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cyclohexadepsipeptide synthetase.

In another preferred embodiment, the cyclohexadepsipeptide synthetase is an *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*,
5 *Penicillium purpurogenum*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cyclohexadepsipeptide synthetase.

In another preferred embodiment, the cyclohexadepsipeptide synthetase is a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium*
10 *culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cyclohexadepsipeptide synthetase.

15 The present invention also relates to isolated nucleic acid sequences that encode a cyclohexadepsipeptide synthetase of the present invention. In a preferred embodiment, the nucleic acid sequence is set forth in SEQ ID NO:1. In another more preferred embodiment, the nucleic acid sequence is the sequences contained in plasmid pZL-ESA, which is contained in *Escherichia coli* NRRL B-30068, plasmid pZL-ESB, which is
20 contained in *Escherichia coli* NRRL B-30069, and plasmid pZL-ESC, which is contained in *Escherichia coli* NRRL B-30070. In another more preferred embodiment, the nucleic acid sequence is the sequences encoding the mature polypeptide contained within SEQ ID NO:2 that is contained in plasmid pZL-ESA, which is contained in *Escherichia coli* NRRL B-30068, plasmid pZL-ESB, which is contained in *Escherichia coli* NRRL B-
25 30069, and plasmid pZL-ESC, which is contained in *Escherichia coli* NRRL B-30070. In another preferred embodiment, the nucleic acid sequence is the mature polypeptide coding region contained within SEQ ID NO:1. The present invention also encompasses nucleic acid sequences that encode a polypeptide having the amino acid sequence of SEQ ID NO:2 or the mature polypeptide thereof, which differ from SEQ ID NO:1 by virtue of
30 the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO:1 that encode fragments of SEQ ID NO:2, which have cyclohexadepsipeptide synthetase activity.

A subsequence of SEQ ID NO:1 is a nucleic acid sequence encompassed by SEQ ID NO:1 except that one or more nucleotides from the 5' and/or 3' end have been deleted. Preferably, a subsequence contains at least 8562 nucleotides, more preferably at least 8862 nucleotides, and most preferably at least 9162 nucleotides.

5 The present invention also relates to mutant nucleic acid sequences comprising at least one mutation in the mature polypeptide coding sequence of SEQ ID NO:1, in which the mutant nucleic acid sequence encodes a polypeptide which consists of the mature polypeptide contained within SEQ ID NO:2.

The techniques used to isolate or clone a nucleic acid sequence encoding a
10 cyclohexadepsipeptide synthetase may include isolation from genomic DNA, preparation from cDNA, or a combination thereof, as described herein. The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, *e.g.*, by PCR or other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification
15 (NASBA) may be used. The nucleic acid sequence may be cloned from a strain of *Fusarium*, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

20 The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence that is essentially free of other nucleic acid sequences, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis.

25 The present invention also relates to nucleic acid sequences that have a degree of homology to the mature polypeptide coding region contained within SEQ ID NO:1 of at least about 65%, preferably about 70%, preferably about 80%, more preferably about 90%, even more preferably about 95%, and most preferably about 97% homology, which encode an active polypeptide. For purposes of the present invention, the degree of
30 homology between two nucleic acid sequences is determined by the Wilbur-Lipman method (Wilbur and Lipman, 1983, *Proceedings of the National Academy of Science USA* 80: 726-730) using the LASERGENE™ MEGALIGN™ software (DNASTAR,

Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10, and gap length penalty of 10. Pairwise alignment parameters were Ktuple=3, gap penalty=3, and windows=20.

Modification of a nucleic acid sequence encoding a cyclohexadepsipeptide
5 synthetase of the present invention may be necessary for the synthesis of polypeptides
substantially similar to the cyclohexadepsipeptide synthetase. The term "substantially
similar" to the cyclohexadepsipeptide synthetase refers to non-naturally occurring forms
of the enzyme. These polypeptides may differ in some engineered way from the
cyclohexadepsipeptide synthetase isolated from its native source, *e.g.*, variants of the
10 cyclohexadepsipeptide synthetase that differ in specific activity, thermostability, pH
optimum, or the like. The variant sequence may be constructed on the basis of the
nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO:1, *e.g.*, a
subsequence thereof, and/or by introduction of nucleotide substitutions that do not give
rise to another amino acid sequence of the polypeptide encoded by the nucleic acid
15 sequence, but which correspond to the codon usage of the host organism intended for
production of the enzyme, or by introduction of nucleotide substitutions that may give
rise to a different amino acid sequence. For a general description of nucleotide
substitution, see, *e.g.*, Ford *et al.*, 1991, *Protein Expression and Purification* 2: 95-107.

It will be apparent to those skilled in the art that such substitutions can be made
20 outside the regions critical to the function of the molecule and still result in an active
polypeptide. Amino acid residues essential to the activity of the cyclohexadepsipeptide
synthetase encoded by the isolated nucleic acid sequence of the invention, and therefore
preferably not subject to substitution, may be identified according to procedures known
in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, *e.g.*,
25 Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique,
mutations are introduced at every positively charged residue in the molecule, and the
resultant mutant molecules are tested for cyclohexadepsipeptide synthetase activity to
identify amino acid residues that are critical to the activity of the molecule. Sites of
substrate-enzyme interaction can also be determined by analysis of the three-dimensional
30 structure as determined by such techniques as nuclear magnetic resonance analysis,
crystallography or photoaffinity labelling (see, *e.g.*, de Vos *et al.*, 1992, *Science* 255:
306-312; Smith *et al.*, 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver *et*

al., 1992, *FEBS Letters* 309: 59-64).

The present invention also relates to isolated nucleic acid sequences encoding a cyclohexadepsipeptide synthetase of the present invention, which hybridize under low stringency conditions, more preferably medium stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions as defined herein with a nucleic acid probe that hybridizes under the same conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii); or allelic variants thereof (Sambrook *et al.*, 1989, *supra*), as defined herein.

10 The present invention also relates to isolated nucleic acid sequences produced by (a) hybridizing a DNA under low, medium, high, or very high stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii), or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the nucleic acid sequence. The subsequence is preferably a sequence of at least
15 100 nucleotides such as a sequence that encodes a polypeptide fragment, which has cyclohexadepsipeptide synthetase activity.

The present invention further relates to methods for producing a mutant nucleic acid sequence, comprising introducing at least one mutation into the mature polypeptide coding sequence of SEQ ID NO:1 or a subsequence thereof, wherein the mutant nucleic
20 acid sequence encodes a polypeptide which consists of the mature polypeptide contained within SEQ ID NO:2 or a fragment thereof that has cyclohexadepsipeptide synthetase activity.

The introduction of a mutation into the nucleic acid sequence to exchange one nucleotide for another nucleotide may be accomplished by site-directed mutagenesis
25 using any of the methods known in the art. Particularly useful is the procedure which utilizes a supercoiled, double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation. The oligonucleotide primers, each complementary to opposite strands of the vector, extend during temperature cycling by means of *Pfu* DNA polymerase. On incorporation of the primers, a mutated plasmid
30 containing staggered nicks is generated. Following temperature cycling, the product is treated with *DpnI* which is specific for methylated and hemimethylated DNA to digest the parental DNA template and to select for mutation-containing synthesized DNA.

Other procedures known in the art may also be used.

The present invention also relates to nucleic acid constructs, recombinant expression vectors, and host cells containing the nucleic acid sequence of SEQ ID NO:1, subsequences or homologues thereof, for expression of the sequences. The constructs
5 and vectors may be constructed as described herein. The host cell may be any cell suitable for the expression of the nucleic acid sequence.

The host cell may be a eukaryote, such as a mammalian cell, an insect cell, a plant cell or a fungal cell. Useful mammalian cells include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS cells, or any number of other
10 immortalized cell lines available, e.g., from the American Type Culture Collection.

In a preferred embodiment, the host cell is a fungal cell. In a more preferred embodiment, the fungal host cell is a yeast cell or a filamentous fungal cell.

In an even more preferred embodiment, the yeast host cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia*
15 cell.

In a most preferred embodiment, the yeast host cell is a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cell. In another most preferred embodiment, the yeast host cell is a
20 *Kluyveromyces lactis* cell. In another most preferred embodiment, the yeast host cell is a *Yarrowia lipolytica* cell.

In another even more preferred embodiment, the filamentous fungal host cell is an *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

In a most preferred embodiment, the filamentous fungal host cell is an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Fusarium bactridioides*, *Fusarium crookwellense* (synonym of *Fusarium cerealis*), *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*,
25 *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*,
30 *Fusarium solani*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, *Fusarium venenatum*, (e.g., *Fusarium venenatum*

(Nirenberg sp. nov.), *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophilum*, *Neurospora crassa*, *Penicillium purpurogenum*, *Thielavia terrestris*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell.

5 Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* and *Fusarium* host cells are described herein. Yeast may be transformed using the procedures described by Becker and Guarente, *In* Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and*
10 *Molecular Biology*, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920.

The present invention also relates to methods for producing a cyclohexadepsipeptide synthetase of the present invention comprising (a) cultivating a
15 strain, which in its wild-type form is capable of producing the cyclohexadepsipeptide synthetase, to produce a supernatant comprising the cyclohexadepsipeptide synthetase; and (b) recovering the cyclohexadepsipeptide synthetase. Preferably, the strain is of the genus *Fusarium*, and more preferably *Fusarium venenatum*.

The present invention also relates to methods for producing a
20 cyclohexadepsipeptide synthetase of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the cyclohexadepsipeptide synthetase; and (b) recovering the cyclohexadepsipeptide synthetase.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the cyclohexadepsipeptide synthetase using
25 methods known in the art as described herein. The cyclohexadepsipeptide synthetase may be detected using methods known in the art specific for the enzyme (see, *e.g.*, Visconti *et al.*, 1992, *supra*). The resulting cyclohexadepsipeptide synthetase may be recovered and purified by methods known in the art as described herein.

The present invention also relates to methods for producing
30 cyclohexadepsipeptides and to cyclohexadepsipeptides produced by the cyclohexadepsipeptide synthetases of the present invention. The production of a cyclohexadepsipeptide may be accomplished with the isolated synthetase or by

fermentation of a cell containing the gene encoding the synthetase (see, for example, Madry *et al.*, 1983, *European Journal of Applied Microbiology and Biotechnology* 17: 75-79). The cell may be a wild-type cell or a recombinant cell. The cyclohexadepsipeptides may be isolated and purified by any of the methods known in the art. See, for example, U.S. Patent No. 5,656,464; Visconti *et al.*, 1992, *supra*.

- In a preferred embodiment, the method for producing a cyclohexadepsipeptide, comprises: (a) reacting a cyclohexadepsipeptide synthetase of the present invention with D-2-hydroxyisovaleric acid, a branched chain L-amino acid, S-adenosylmethionine, and ATP; and
- (b) isolating the cyclohexadepsipeptide from the reaction.

- In another preferred embodiment, the method for producing a cyclohexadepsipeptide, comprises: (a) cultivating a cell under conditions suitable for the production of the cyclohexadepsipeptide, wherein the cell comprises a nucleic acid sequence encoding (i) a cyclohexadepsipeptide synthetase having an amino acid sequence which has at least 65% identity with the mature polypeptide contained within SEQ ID NO:2; (ii) a cyclohexadepsipeptide synthetase which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with the nucleic acid sequence of SEQ ID NO:1 or its complementary strand, or a subsequence of SEQ ID NO:1 of at least 100 nucleotides; (iii) an allelic variant of (a) or (b); or (iv) a fragment of (a), (b), or (c) that has cyclohexadepsipeptide synthetase activity; and (b) isolating the cyclohexadepsipeptide from the reaction.

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

Examples

Strains

Fusarium venenatum strain ATCC 20334 was used as the source of genomic DNA for these experiments. Genomic DNA libraries were constructed using the λZipLox cloning system (Life Technologies, Gaithersburg, MD) with *E. coli* Y1090ZL as a host for plating and purification of recombinant bacteriophage and *E. coli* DH10Bzip for excision of recombinant pZL1-derivatives. *Fusarium torulosum* R-5690 (*Fusarium*

Research Center, Penn State University, State College, PA) and *Aspergillus niger* Bo-1 (Novo Nordisk A/S, Bagsvaerd, Denmark) were used as sources of control DNAs for hybridization experiments. The *tri5*-deleted *Fusarium venenatum* strain LyMC1A (WO 99/60137) was used as the recipient for transformation experiments. *Escherichia coli* TOP10 (Invitrogen Corp., Carlsbad, CA) and *E. coli* DH5-alpha strains (Gibco-BRL Life Technologies, Bethesda, MD) were used for vector construction and routine plasmid propagation.

Media

10 RA sporulation medium was composed per liter of 50 g of succinic acid (disodium salt), 20 ml of 50X Vogels salts, 12.1 g of NaNO_3 , and 1 g of glucose.

50X Vogels Salts was composed per liter of 125 g of sodium citrate, 250 g of KH_2PO_4 , 10 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 5 g of $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ (predissolved in 20 ml water), and 5 ml of 200X Vogels trace elements. (Each ingredient was dissolved completely before
15 addition of the next one). Filter sterilized.

200 X Vogels Trace Elements was composed per 100 ml of 5g of citric acid $\cdot 1\text{H}_2\text{O}$, 5 g of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 1 g of $\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2 \cdot 6\text{H}_2\text{O}$, 0.25 g of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 0.05 g of $\text{MnSO}_4 \cdot 1\text{H}_2\text{O}$, 0.05 g of H_3BO_3 , and 0.05 g of $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$.

Fluoroacetamide agar (FA) was composed per liter of 12g of sodium acetate, 2 g of sodium chloride, 0.5 g of MgSO_4 , 3 g of KH_2PO_4 , 0.3 g of urea, 2 g of fluoroacetamide, 1 ml of Vogels salts, and 15 g of Noble agar (pH 6.1).
20

Cove medium was composed per liter of 342.3 g of sucrose, 20 ml of 50X Cove salt solution, 10 ml of 1 M acetamide, 10 ml of 1.5 M CsCl, and 25 g of Noble agar.

50X Cove Salts was composed per liter of 26g of KCl, 26 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 76g of KH_2PO_4 , and 50 ml of 20X Cove trace elements.
25

20X Cove trace elements was composed per liter of 0.04 g of $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$, 0.4 g of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 1.2 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.7 g of $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, 0.8 g of $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$, and 10 g of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$.

30 Example 1: Genomic DNA Extraction of *Fusarium venenatum*, *Fusarium torulosum*, and *Aspergillus niger*

Fusarium venenatum, *Fusarium torulosum*, and *Aspergillus niger* were each

grown for 24-36 hours at 28°C and 150 rpm in 25 ml of YEG medium composed per liter of 5 g of yeast extract and 20 g of glucose. Mycelia were then collected by filtration through Miracloth (Calbiochem, La Jolla, CA) and washed once with 25 ml of 10 mM Tris-1 mM EDTA (TE) buffer. Excess buffer was drained from the mycelia which were
5 subsequently frozen in liquid nitrogen. The frozen mycelia were ground to a fine powder in an electric coffee grinder, and each powder was added to 20 ml of TE buffer and 5 ml of 20% w/v sodium dodecylsulfate (SDS) in a disposable plastic centrifuge tube. The mixtures were gently inverted several times to ensure mixing, and extracted twice with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v). Sodium acetate (3
10 M solution) was added to give a final concentration of 0.3 M and the nucleic acids were precipitated with 2.5 volumes of ice cold ethanol. The tubes were centrifuged at 15,000 x g for 30 minutes and the pellets were allowed to air dry for 30 minutes before resuspension in 0.5 ml of TE buffer. DNase-free ribonuclease A was added to a concentration of 100 µg/ml and the mixtures were incubated at 37°C for 30 minutes.
15 Proteinase K (200 µg/ml) was then added and the mixtures were incubated an additional hour at 37°C. Finally, the mixtures were extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) before precipitating the DNA with sodium acetate and ethanol according to standard procedures. The DNA pellets were dried under vacuum, resuspended in TE buffer, and stored at 4°C.

20

Example 2: Hybridization Experiments

The genomic DNA preparations described in Example 1 were tested for the presence of cyclohexadepsipeptide synthetase gene sequences using Southern hybridization. Aliquots of the DNA were digested with *Bam*HI or *Bam*HI plus *Xba*I and
25 fractionated by agarose gel electrophoresis. The DNA in the gel was blotted to a Hybond N+™ membrane filter (Amersham Corporation, Arlington Heights, IL) according to the method of Davis *et al.* (1980, *Advanced Bacterial Genetics, A Manual for Genetic Engineering*, Cold Spring Harbor Press, Cold Spring Harbor, NY), and probed with a radiolabeled fragment encoding the 5' portion of the *Fusarium torulosum esyn1* gene
30 (obtained from Dr. Thomas Hohn, USDA, Peoria, IL) under low, medium, and high stringency hybridization conditions at 45°C as described herein. The cyclohexadepsipeptide synthetase-specific probe fragment from *Fusarium torulosum* was

radiolabeled by nick translation (Sambrook *et al.*, 1989, *Molecular Cloning. A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, NY) with α [32 P]dCTP (Amersham, Arlington Heights, IL), denatured by adding NaOH to a final concentration of 0.1 M, and added to the hybridization buffer at an activity of approximately 1×10^6 cpm per ml. Following the hybridization, the filters were washed once in 0.2X SSPE with 0.1% SDS at 45°C followed by two washes in 0.2X SSPE (no SDS) at the same temperature. The filters were allowed to dry on paper towels for 15 minutes, then wrapped in Saran-wrap™ and exposed to X-ray film overnight at -70°C with intensifying screens (Kodak, Rochester, NY).

10 Southern hybridization analysis showed that cyclohexadepsipeptide synthetase-specific DNA sequences could be detected in the genome of *Fusarium venenatum* with the *Fusarium torulosum esyn1* probe only under conditions of low and medium stringency. The positive control DNA from *Fusarium torulosum* gave strong hybridization signals under all conditions, and negative control DNA from *Aspergillus*
15 *niger* failed to hybridize under all conditions tested. These results suggested that *Fusarium venenatum* contained genomic DNA sequences homologous to the *Fusarium torulosum* enniatin synthetase gene.

Example 3: Genomic DNA Library Construction and Screening

20 Genomic libraries of *Fusarium venenatum* were constructed in λ ZipLox according to the manufacturer's instructions (Life Technologies, Gaithersburg, MD). *Fusarium venenatum* genomic DNA was partially digested with *Tsp509I* and size-fractionated on 1% agarose gels. DNA fragments migrating in the size range 3-7 kb were excised and eluted from the agarose gel slices using Prep-a-Gene reagents (BioRad,
25 Hercules, CA). The eluted DNA fragments were ligated with *EcoRI*-cleaved and dephosphorylated λ ZipLox vector arms (Life Technologies, Gaithersburg, MD), and the ligation mixtures were packaged using commercial packaging extracts (Stratagene, La Jolla, CA). The packaged DNA libraries were plated and amplified in *E. coli* Y1090ZL cells.

30 Approximately 50,000 plaques from the library were screened by plaque-hybridization (Davis *et al.*, 1980, *supra*) with the radiolabeled probe fragment of the *Fusarium torulosum esyn1* gene using the low stringency conditions described in

Example 2. Plaques, which gave hybridization signals, were purified twice in *E. coli* Y1090ZL cells, and the individual clones were subsequently excised from the λ ZipLox vector as pZL1-derivatives (D'Alessio *et al.*, 1992, *Focus*® 14: 7). Chromosome "walking" to obtain adjacent DNA sequences was done using homologous *Fusarium venenatum* probes at high stringency.

Four plaques were identified that hybridized strongly to the *Fusarium torulosum* *esyn1* gene probe, and each of the potential clones was subsequently excised from the λ ZipLox vector as a pZL1-derivative (D'Alessio *et al.*, 1992, *supra*). Plasmid DNA was isolated from the clones by passage through *E. coli* DH10B cells using standard methods.

10 The sizes of the cloned inserts were determined by agarose gel electrophoresis. The largest insert comprised a DNA segment of approximately 3 kb. The clone was designated *E. coli* DH10B pZL-ESA.

Example 4: Cloning and Analysis of a *Fusarium venenatum* Cyclohexadepsipeptide Synthetase Gene

DNA sequencing of the DNA segment of approximately 3 kb was performed with an Applied Biosystems Model 377 XL Automated DNA Sequencer using dye-terminator chemistry. Contiguous sequences were generated using a transposon insertion strategy (Primer Island Transposition Kit, Perkin-Elmer/Applied Biosystems, Inc., Foster City, CA).

20 The entire cloned region was sequenced to an average redundancy of 6.9.

Nucleotide sequencing revealed that the 3 kb segment contained an open reading frame encoding at least 900 amino acids. However, this fragment (designated Fragment A, pZL-ESA) did not encode the entire gene product. Consequently, the library was re-screened using a probe comprising the 3'-portion of Fragment A (ca. 1 kb *HindIII* fragment).

25 Several clones were subsequently identified and analyzed by restriction mapping. The largest of these secondary clones contained a genomic DNA insert of about 4.6 kb (designated Fragment B, pZL-ESB). The clone was designated *E. coli* DH10B pZL-ESB.

Nucleotide sequence examination of Fragment B extended the open reading frame of Fragment A by amino acids 777 through 2311. However, this sequence did not reach the stop codon of the open reading frame, thereby necessitating isolation of a third genomic segment. The third genomic clone was isolated by re-screening the genomic

30

library with a PCR-amplified probe derived from Fragment B. Two PCR primers shown below were used to amplify a 586 bp probe segment used for screening the library.

5'-dAATTGATTTCGCTTGAAAGTCGAT-3' (SEQ ID NO:3)

5'-dCTTGAGAGTTACGTTGGTCTTGAAC-3' (SEQ ID NO:4)

5 The amplification reaction (100 µl) contained the following components: 0.2 µg of pZL-ESB DNA, 48.4 pmol of the forward primer, 48.4 pmol of the reverse primer, 1 mM each of dATP, dCTP, dGTP, and dTTP, 1 x *Taq* polymerase buffer, and 2.5 U of *Taq* polymerase (Perkin-Elmer Corp., Branchburg, NJ). The reaction was incubated in an Ericomp Twin Block System Easy Cyclor programmed for 1 cycle at 95°C for 5
10 minutes followed by 30 cycles each at 95°C for 1 minute, 55°C for 1 minute and 72°C for 2 minutes.

The reaction was electrophoresed on an agarose gel, and the expected product of 586 bp was obtained. The reaction was run on a preparative gel, a gel slice containing the desired product was excised, and DNA was isolated from the gel using a Qiaquick
15 Gel Extraction Kit (Qiagen, Chatsworth, CA).

From seven clones that were identified with this probe, the largest (Fragment C, pZL-ESC) contained a 5.5 kb insert. Subsequent DNA sequence analysis revealed that Fragment C encoded amino acids 1617 through 3129, a potential stop codon, and 1553 bp of 3'-flanking DNA. The clone was designated *E. coli* DH10B pZL-ESC. The entire
20 DNA sequence of the cyclohexadepsipeptide synthetase gene was assembled from the three overlapping clones (Fragments A, B, and C). A transposon insertion strategy allowed for rapid sequencing to high redundancy.

The complete DNA sequence and deduced amino acid sequence are shown in Figure 1. The DNA sequence of the cyclohexadepsipeptide synthetase gene (SEQ ID
25 NO:1) was determined to an average redundancy of 6.9. The cyclohexadepsipeptide synthetase gene contained a lengthy open reading frame of 9387 bp with no introns, encoding a polypeptide of 3129 amino acids (MW = 346,852).

The deduced amino acid sequence (SEQ ID NO:2) of the cyclohexadepsipeptide synthetase gene product shared approximately 59% identity to the enniatin synthetase of
30 *Fusarium scirpi* (Haese *et al.*, 1993, *Mol. Microbiol.* 7: 905-914; DNA sequence listed in EMBL database under accession number Z18755). Percent identity was determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) using the LASERGENE™

MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10 and gap length penalty of 10. Pairwise alignment parameters were Ktuple=1, gap penalty=3, windows=5, and diagonals=5.

5

Example 5: pΔES-*amdS* Construction

The construction of the *dps1* deletion vectors pΔES-*amdS1* and pΔES-*amdS2* is shown in Figure 2. Briefly, a 0.2 kb DNA segment comprising a portion of the *dps1* coding region was removed from plasmid pZL-ESA (designated as fragment A) by
10 digestion with *Sst*I and *Nru*I restriction endonucleases. Both of these enzymes generate blunt-ended DNA fragments. The digested pESA vector was treated with calf intestine alkaline phosphatase (Boehringer-Mannheim Biochemicals, Indianapolis, IN) to prevent self-ligation. Lastly, a 3.2 kb fragment encoding the *Aspergillus nidulans amdS* gene (with flanking repeat sequences derived from the *Aspergillus oryzae pyrG* gene) was
15 obtained by digestion of pJRoy47 (WO 99/60137) with *Sma*I and *Pme*I. This *amdS* fragment was subsequently ligated with the pZL-ESA vector fragment described above to generate the deletion plasmids pΔES-*amdS1* and pΔES-*amdS2* (which differ only in the orientation of the *amdS* gene segment).

20 Example 6: Transformation of *Fusarium venenatum* LyMC1A and Preliminary Screening for *dps1* Gene Deletions

Plasmid pΔES-*amdS1* was digested with *Spe*I, and the 5.7 kb deletion fragment (comprising portions of the *Fusarium venenatum dps1* gene with the *Aspergillus nidulans amdS* gene and repeats replacing 0.2 kb of the *dps1* coding region) was
25 subsequently excised and purified for use in transformation experiments. The preparation and transformation of *Fusarium venenatum* LyMC1A protoplasts was performed according to the method of Royer, 1995, *Bio/Technology* 13: 1479-1483.

Fusarium venenatum LyMC1A protoplasts were transformed with the 5.7 kb *Spe*I ΔES-*amdS* fragment with selection on COVE plates. Fifteen transformants were
30 obtained and single spore purified. DNA was extracted from the single spore purified transformants, generated with the *Spe*I ΔES-*amdS* fragment, as well as from *Fusarium venenatum* LyMC1A, using the Qiagen DNeasy Plant mini kit (Qiagen, Chatsworth, CA)

(with a 2 hour lytic incubation in place of 10 minutes recommended in the manufacturer's protocol). One to two micrograms of each DNA were digested for seven hours with *XhoI* or *SpeI* (10 U/ μ g DNA in 30 μ l reactions). The digests were electrophoresed on 1% agarose gels in TAE buffer, and the DNAs were transferred to
5 Hybond N⁺ in 0.4 N NaOH. The blots were UV crosslinked and probed as described below.

Probes were prepared using the Prime-It Labeling Kit (Stratagene, La Jolla, CA) and α [³²P]-dCTP. Following labeling the probes were separated from unincorporated label using a G 50 TE Midi column (5' to 3', Boulder, CO).

10 Blots were prehybridized at 65°C in Rapid Hyb Buffer (Amersham, Arlington Heights, IL) for 45 minutes. Denatured probes were added to the Rapid Hyb solution and hybridizations were done overnight at 65°C. Following hybridization the blots were washed once at room temperature in 2X SSC for 5 minutes and in 0.2X SSC, 0.1% SDS at 65°C for 5 minutes twice. The washed blots were washed in 2X SSC at room
15 temperature for 5 minutes.

Southern blots of *XhoI* and *SpeI*-digested genomic DNA were probed twice. First, they were probed with an 800 bp *NsiI/SpeI* fragment of p Δ ES-*amdS1*. Four of the fifteen transformants had the 5.2 kb band (*XhoI* digested DNA) and the 5.7 kb band (*SpeI* digested DNA) expected for a gene replacement when probed with the 800 bp *NsiI/SpeI*
20 fragment. Most of the other transformants had the 2.2 kb band (*XhoI* digested DNA) or the 2.7 kb (*SpeI* digested DNA) wild-type bands, and additional bands, most likely corresponding to ectopic integration of the transforming DNA.

Secondly, the same Southern blots were probed with *HindIII*-linearized pDSY176, a plasmid containing the 0.2 kb *StuI/NruI* portion of the *dps1* coding region.
25 pDSY176 was constructed as follows: pZL-ESA was digested with *StuI/NruI*, and the 0.2 kb fragment was isolated by preparative electrophoresis. The isolated fragment was cloned into pZERO-Blunt (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions to produce pDSY176. Hybridization analysis using this second probe (pDSY176) confirmed that none of the four putative deleted strains
30 (*Fusarium venenatum* Δ ES 4, 6, 8, and 10) contained the 0.2 kb region of the *dps1* gene which had been deleted.

Example 7: Removal of the *amdS* Gene

Two of the transformants confirmed as being deleted, Δ ES4A and Δ ES8A, were sporulated in 500 ml of RA medium, in 2 liter Fernbach flasks. These were inoculated with 12 mycelial plugs cut from Cove plates and incubated at 24°C, 150 rpm for 53 hours. After this time spores were harvested through sterile Miracloth (Calbiochem, San Diego, CA) centrifuged for 30 minutes at 7,000 rpm in a Sorval GS3 rotor and washed three times with sterile water. Freshly harvested spores were plated at 10^4 , 10^5 and 10^6 per plate (five plates at each concentration) of FA. Colonies which grew on these plates were picked to FA and Cove plates.

10 Numerous colonies were obtained on FA plates (primarily from plates seeded with 10^5 and 10^6 spores/plate) which, on subculturing, grew well on FA but only sparsely on Cove. Thirty two Δ ES4A-derived colonies (designated as *Fusarium venenatum* WTY700-3-4) and 128 Δ ES8A-derived colonies (designated as *Fusarium venenatum* WTY700-3-8) all had an *amdS*-minus phenotype.

15 DNA was extracted from five *Fusarium venenatum* WTY700-3-4 isolates (WTY700-3-4a through 4e) and ten *Fusarium venenatum* WTY700-3-8 strains (WTY700-3-8a through 8j) as well as LyMC1A, Δ ES4A and Δ ES8A using the Qiagen DNeasy Plant Mini Kit (with a 2 hour lytic incubation in place of 10 min recommended in the manufacturer's protocol). One microgram of each DNA was digested overnight with *XhoI* and *SpeI* (20 U/ μ g DNA in 50 μ l reactions). The digests were concentrated to 20 10 μ l and run on 1% agarose gels in TBE. DNAs were transferred to Hybond N+ membranes using the manufacturer's protocol, and were then probed with the probes described in Example 6.

Hybridization analysis of genomic DNAs extracted from these strains (using the 25 800 bp *NsiI-SpeI* fragment of Δ ES-*amdS* and *HindIII*-digested pDSY176 (which contains the 200 bp *StuI-NruI* portion of the *dpsI* open reading frame) revealed that none of the WTY700-3-4 isolates had lost the *amdS* gene, but 50% (5/10) of the *Fusarium venenatum* WTY700-3-8 isolates showed a banding pattern consistent with removal of the *amdS* gene. Hybridization analysis, thus, confirmed that *Fusarium venenatum* 30 WTY700-3-8a, b, c, d, and e were deleted for the 200 bp *StuI/NruI* portion of the *dpsI* open reading frame. As expected for a deletion, a hybridization signal was observed using the pDSY176 probe described above for the parent strain *Fusarium venenatum*

LyMC1A but not for any of the five *Fusarium venenatum* WTY700-3-8a-e strains.

Deposit of Biological Materials

5 The following biological materials have been deposited under the terms of the Budapest Treaty with the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL), Peoria, Illinois, and given the following accession numbers:

	Deposit	Accession Number	Date of Deposit
10	<i>E. coli</i> DH10B (pZL-ESA)	NRRL B-30068	October 27, 1998
	<i>E. coli</i> DH10B (pZL-ESB)	NRRL B-30069	October 27, 1998
	<i>E. coli</i> DH10B (pZL-ESC)	NRRL B-30070	October 27, 1998

15 The strains have been deposited under conditions that assure that access to the cultures will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122. The deposits represent substantially pure cultures of the deposited strains. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a
20 license to practice the subject invention in derogation of patent rights granted by governmental action.

25 The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. In the case of conflict, the present
30 disclosure including definitions will control.

 Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>41</u> , line <u>10</u>	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit October 27, 1998	Accession Number NRRL B-30068
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

<p style="text-align: center; margin: 0;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> This sheet was received with the international application </div> <div style="border: 1px solid black; height: 20px; margin-bottom: 5px;"></div> <div style="border: 1px solid black; height: 20px; margin-bottom: 5px;"></div> <div style="border: 1px solid black; padding: 5px;"> Authorized officer </div>	<p style="text-align: center; margin: 0;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> This sheet was received with the International Bureau on: </div> <div style="border: 1px solid black; height: 20px; margin-bottom: 5px;"></div> <div style="border: 1px solid black; height: 20px; margin-bottom: 5px;"></div> <div style="border: 1px solid black; padding: 5px;"> Authorized officer </div>
--	--


Form PCT/RO/134 (July 1992)

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>41</u> , line <u>11</u>	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL) Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit October 27, 1998	Accession Number NRRL B-30069
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application
Authorized officer 

Form PCT/RO/134 (July 1992)

For International Bureau use only


This sheet was received with the International Bureau on:
Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>41</u> , line <u>12</u>	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution <p style="text-align: center;">Agricultural Research Service Patent Culture Collection (NRRL)</p> Address of depository institution (including postal code and country) <p style="text-align: center;">Northern Regional Research Center 1815 University Street Peoria, IL 61604, US</p>	
Date of deposit October 27, 1998	Accession Number NRRL B-30070
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No. 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

This sheet was received with the international application
Authorized officer 

Form PCT/RO/134 (July 1992)

For International Bureau use only

This sheet was received with the International Bureau on:
Authorized officer

Claims

What is claimed is:

1. A method for producing a heterologous polypeptide, comprising:
 - (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wherein (i) the mutant comprises a first nucleic acid sequence encoding the heterologous polypeptide, and (ii) the mutant produces less of a cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under the same conditions; and
 - (b) isolating the heterologous polypeptide from the cultivation medium.
2. The method of claim 1, wherein the filamentous fungal cell is an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Gibberella*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Myrothecium*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.
3. The method of claim 1, wherein the filamentous fungal cell is a *Fusarium* cell.
4. The method of claim 3, wherein the *Fusarium* cell is a *Fusarium venenatum* cell.
5. The method of claim 4, wherein the *Fusarium venenatum* cell is *Fusarium venenatum* ATCC 20334.
6. The method of claim 4, wherein the *Fusarium venenatum* cell is a morphological mutant.
7. The method of claim 6, wherein the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* ATCC 20334.

8. The method of any of claims 1-7, wherein the mutant cell comprises a second nucleic acid sequence which comprises a modification of at least one of the genes involved in the production of the cyclohexadepsipeptide.
9. The method of claim 8, wherein the genes are selected from the group consisting of a cyclohexadepsipeptide synthetase gene, enniatin synthetase gene, and D-hydroxyisovalerate dehydrogenase gene.
10. The method of claim 8, wherein one of the genes is a cyclohexadepsipeptide synthetase gene.
11. The method of claim 8, wherein one of the genes is an enniatin synthetase gene.
12. The method of claim 8, wherein one of the genes is a D-hydroxyisovalerate dehydrogenase gene.
13. The method of any of claims 1-12, wherein the mutant cell produces at least about 25% less of the cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under identical conditions.
14. The method of any of claims 1-13, wherein the mutant cell produces no cyclohexadepsipeptide.
15. The method of any of claims 1-14, wherein the filamentous fungal cell comprises at least two copies of the first nucleic acid sequence.
16. The method of any of claims 1-15, wherein the heterologous polypeptide is a hormone, hormone variant, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter.
17. The method of claim 16, wherein the enzyme is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase.

18. The method of claim 17, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.
19. The method of any of claims 1-18, wherein the mutant cell further comprises one or more modifications of one or more third nucleic acid sequences, wherein the modification reduces or eliminates expression of the one or more third nucleic acid sequences.
20. The method of claim 19, wherein the third nucleic acid sequence encodes an enzyme selected from the group consisting of an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.
21. The method of any of claims 19, wherein the third nucleic acid sequence encodes a protease.
22. A cyclohexadepsipeptide-deficient mutant of a filamentous fungal cell, comprising a first nucleic acid sequence encoding a heterologous polypeptide, wherein the mutant produces less of a cyclohexadepsipeptide than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.
23. The mutant cell of claim 22, wherein the mutant cell comprises a second nucleic acid sequence which comprises a modification of at least one of the genes involved in the production of the cyclohexadepsipeptide.

24. The mutant cell of claim 23, wherein the genes are selected from the group consisting of a cyclohexadepsipeptide synthetase gene, enniatin synthetase gene, and D-hydroxyisovalerate dehydrogenase gene.
25. The mutant cell of claim 23, wherein one of the genes is a cyclohexadepsipeptide synthetase gene.
26. The mutant cell of claim 23, wherein one of the genes is an enniatin synthetase gene.
27. The mutant cell of claim 23, wherein one of the genes is a D-hydroxyisovalerate dehydrogenase gene.
28. The mutant cell of any of claims 22-27, wherein the cell comprises at least two copies of the first nucleic acid sequence.
29. A method for obtaining the mutant cell of any of claims 22-28, comprising:
- (a) introducing into a parent filamentous fungal cell a first nucleic acid sequence encoding a heterologous polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the production of a cyclohexadepsipeptide; and
 - (b) identifying the mutant from step (a), wherein the mutant produces less of the cyclohexadepsipeptide than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.
30. An isolated cyclohexadepsipeptide synthetase, selected from the group consisting of:
- (a) a cyclohexadepsipeptide synthetase having an amino acid sequence which has at least 65% identity with the mature polypeptide contained within SEQ ID NO:2;
 - (b) a cyclohexadepsipeptide synthetase which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);
 - (c) an allelic variant of (a) or (b); and

(d) a fragment of (a), (b), or (c) that has cyclohexadepsipeptide synthetase activity.

31. The cyclohexadepsipeptide synthetase of claim 30, having an amino acid sequence which has at least 65% identity with the mature polypeptide contained within SEQ ID NO:2.

32. The cyclohexadepsipeptide synthetase of claim 31, having an amino acid sequence which has at least 70% identity with the mature polypeptide contained within SEQ ID NO:2.

33. The cyclohexadepsipeptide synthetase of claim 32, having an amino acid sequence which has at least 80% identity with the mature polypeptide contained within SEQ ID NO:2.

34. The cyclohexadepsipeptide synthetase of claim 33, having an amino acid sequence which has at least 90% identity with the mature polypeptide contained within SEQ ID NO:2.

35. The cyclohexadepsipeptide synthetase of claim 34, having an amino acid sequence which has at least 95% identity with the mature polypeptide contained within SEQ ID NO:2.

36. The cyclohexadepsipeptide synthetase of claim 30, comprising the amino acid sequence of SEQ ID NO:2.

37. The cyclohexadepsipeptide synthetase of claim 30, consisting of the amino acid sequence of SEQ ID NO:2 or a fragment thereof.

38. The cyclohexadepsipeptide synthetase of claim 37, consisting of the amino acid sequence of SEQ ID NO:2.

39. The cyclohexadepsipeptide synthetase of claim 38, which consists of the mature polypeptide contained within SEQ ID NO:2.

40. The cyclohexadepsipeptide synthetase of any of claims 30-39, which is obtained from a *Fusarium* strain.

41. The cyclohexadepsipeptide synthetase of claim 40, which is obtained from *Fusarium venenatum* strain.
42. The cyclohexadepsipeptide synthetase of claim 30, which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);.
43. The cyclohexadepsipeptide synthetase of claim 42, which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, or (iii) a complementary strand of (i) or (ii).
44. The cyclohexadepsipeptide synthetase of claim 42 or 43, which is obtained from a *Fusarium* strain.
45. The cyclohexadepsipeptide synthetase of claim 44, which is obtained from *Fusarium venenatum* strain.
46. The cyclohexadepsipeptide synthetase of claim 30, which is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii).
47. The cyclohexadepsipeptide synthetase of claim 46, which is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, or (iii) a complementary strand of (i), (ii), or (iii);.
48. The cyclohexadepsipeptide synthetase of claim 46 or 47, which is obtained from a *Fusarium* strain.

49. The cyclohexadepsipeptide synthetase of claim 48, which is obtained from *Fusarium venenatum* strain.

50. The cyclohexadepsipeptide synthetase of claim 30, which is encoded by the nucleic acid sequences contained in plasmid pZL-ESA, which is contained in *Escherichia coli* NRRL B-30068, plasmid pZL-ESB, which is contained in *Escherichia coli* NRRL B-30069, and plasmid pZL-ESC, which is contained in *Escherichia coli* NRRL B-30070.

51. The cyclohexadepsipeptide synthetase of any of claims 30-50 which has at least 20% of the enzyme activity of SEQ ID NO:2.

52. A cyclohexadepsipeptide synthetase having the same enzyme activity as the cyclohexadepsipeptide synthetase of any of claims 30-51.

53. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the cyclohexadepsipeptide synthetase of any of claims 30-52.

54. An isolated nucleic acid sequence comprising a nucleic acid sequence having at least one mutation in the mature cyclohexadepsipeptide synthetase coding sequence of SEQ ID NO:1, in which the mutant nucleic acid sequence encodes a cyclohexadepsipeptide synthetase consisting of the mature polypeptide contained within SEQ ID NO:2.

55. An isolated nucleic acid sequence produced by (a) hybridizing a DNA under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the nucleic acid sequence.

56. The isolated nucleic acid sequence of claim 55 produced by (a) hybridizing a DNA under high stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) the cDNA sequence of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the nucleic acid sequence.

57. A nucleic acid construct comprising the nucleic acid sequence of claim 53 operably linked to one or more control sequences that direct the production of the cyclohexadepsipeptide synthetase in a suitable expression host.
58. A recombinant expression vector comprising the nucleic acid construct of claim 57.
59. A recombinant host cell comprising the nucleic acid construct of claim 57.
60. A method for producing a mutant nucleic acid sequence, comprising (a) introducing at least one mutation into the mature cyclohexadepsipeptide synthetase coding sequence of SEQ ID NO:1, wherein the mutant nucleic acid sequence encodes a cyclohexadepsipeptide synthetase consisting of the mature polypeptide contained within SEQ ID NO:2; and (b) recovering the mutant nucleic acid sequence.
61. A mutant nucleic acid sequence produced by the method of claim 60.
62. A method for producing a cyclohexadepsipeptide synthetase, comprising (a) cultivating a strain comprising the mutant nucleic acid sequence of claim 61 encoding the cyclohexadepsipeptide synthetase to produce a supernatant comprising the cyclohexadepsipeptide synthetase; and (b) recovering the cyclohexadepsipeptide synthetase.
63. A method for producing the cyclohexadepsipeptide synthetase of any of claims 30-52 comprising (a) cultivating a strain to produce a supernatant comprising the cyclohexadepsipeptide synthetase; and (b) recovering the cyclohexadepsipeptide synthetase.
64. A method for producing the cyclohexadepsipeptide synthetase of any of claims 30-52 comprising (a) cultivating a host cell comprising a nucleic acid construct comprising a nucleic acid sequence encoding the cyclohexadepsipeptide synthetase under conditions suitable for production of the cyclohexadepsipeptide synthetase; and (b) recovering the cyclohexadepsipeptide synthetase.
65. A method for producing a cyclohexadepsipeptide synthetase comprising (a) cultivating a host cell under conditions conducive for production of the

cyclohexadepsipeptide synthetase, wherein the host cell comprises a mutant nucleic acid sequence having at least one mutation in the mature cyclohexadepsipeptide synthetase coding sequence of SEQ ID NO:1, wherein the mutant nucleic acid sequence encodes a cyclohexadepsipeptide synthetase consisting of the mature polypeptide contained within SEQ ID NO:2, and (b) recovering the cyclohexadepsipeptide synthetase.

66. A method for producing a cyclohexadepsipeptide, comprising:

(a) reacting the cyclohexadepsipeptide synthetase of any of claims 30-52 with D-2-hydroxyisovaleric acid, a branched chain L-amino acid, S-adenosylmethionine, and ATP; and

(b) isolating the cyclohexadepsipeptide from the reaction.

67. A cyclohexadepsipeptide produced by the method of claim 66.

68. A method for producing a cyclohexadepsipeptide, comprising:

(a) cultivating a cell under conditions suitable for the production of the cyclohexadepsipeptide, wherein the cell comprises a nucleic acid sequence encoding (i) a cyclohexadepsipeptide synthetase having an amino acid sequence which has at least 65% identity with the mature polypeptide contained within SEQ ID NO:2; (ii) a cyclohexadepsipeptide synthetase which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with the nucleic acid sequence of SEQ ID NO:1 or its complementary strand, or a subsequence of SEQ ID NO:1 of at least 100 nucleotides; (iii) an allelic variant of (a) or (b); or (iv) a fragment of (a), (b), or (c) that has cyclohexadepsipeptide synthetase activity; and

(b) isolating the cyclohexadepsipeptide from the reaction.

A cyclohexadepsipeptide produced by the method of claim 68.

1/10

AATTAGATTCCACTAGTACGCCATTGTAGAATCAAGGCCAAGATATGAACAACCCATAAGTAACGGCGATCCTGTCTCAT 80
 GTATCCAAAAATAAGAGACACGGCATATTCACTGCTTTGCAGATCTTTCTCAAATCTCTCCCTCGAGAAGCTACTGGGA 160
 TGAATGAGTCTCTTGGCTCAGATTAGATATCTACTGTATCTGCCGATAGACTTTGCGCTGGTAGCATTAACGTTCTCTA 240
 TATTCTATTATCAAAATCCTTACATTCAATATGGAATATCTTACTGCTGTCGATGGTAGGCAAGACCTGCCACCTACACCA 320
 GCTTCGTTTTGTAGTCATGGAGATAGTCCCTCAATAGCTTTACGAGCAACTCTTCCATCTCTATGGTCTGGATTCGAG 400
 ASFCSHGDSPLNSSEYEQLFHLYGLDSST
 TCGCATCGAAGCTATCAAACCATGCACACCTTTCCAGCTTGACATGATCGACTGCAATGCTTTGGATAAGCAGTCTGCTA 480
 RIEAIAKPCFPFQLDLDMIDCNALDLKQSA
 TCGGCCATGCGGTGTATGATGTCCCAACCGACATTGACATCTCTCGTTTCGGCTTGCGTGAAGGAGATCGTCAACCAA 560
 IGHAVYDVPTDIDISRFALAWKEIVNQ
 ACCCAGCCTTGGGAGCCTTTGCCCTTCACCTCGGACTCTGGAAGACTTCTCAAGTCATCTCTAAAGATAGCTTTGTCTT 640
 TPALRLRAFAFTSDSGKTSQVILKDSFFV
 CTCATGGATGTGCTGCTCTCTTCGAGCTCCCGATGAAGTGGTTCCGGATGAAGCTGCCGCTGCTGCATCCGGGCCAC 720
 SWMCWSSSSSPDEVRDEAAASGP
 GCTGCAACCGCTTCGTTCTACTTGAAGACATGCAGACGAAGAAATGTCAGTGGTTTGGACCTTCAGTCATGCAATTGGTA 800
 RCNRFVLLLEDMMQTKKCLVWTFSHA
 LV
 GACGTCACTTTCCAAACAACGCGTCCTGAGCGGTGTTTCGGGCTTACAAGCATGAGAAGGACACACATCGGCGCTGAGAC 880
 DVTFAQQRVLSRVFAAYKHEDTHRPE
 T
 ACCCGAGTCATCTGATGCCACTGACACTGACTCTCAGTCAGTCTCCGTGGTCTCCATGAGCTGCGAGGACAATGCCGTAT 960
 PESSDATDTDSQSVVSMSCEDNAV
 CGGCGACTCATTTCTGGCAAACCTACCTTAACGATCTCAATGCGTCCGTCTTCCCTCACCTGTCTGACCACCTGATGGTG 1040
 SA THFWQTHLNLNDLNASVFPHLSDHLMV
 CCAACCCAACTACAACAGCAGAGCATCGTATCACATTCCTCTTTACAGAAAGCACTATCCAATTTGCCATCTGCCG 1120
 PNP TTTAEHRI TFP L S Q K A L S N S A I C R
 TACTGCACTCTCAATACTCTCTCGCGCTACACTCACTCTGACGAGGCGCTTGTGTCGGGTAACCTGAGCAATCTCTAC 1200
 TALSILLSRYTHSDEALFGAVTEQSL
 CATTTGACAAACACTATCTTGCAGATGGTACGTAACCAAGTTGCACCCCTTCTGCTGTAACCTGCCAATCAATCTTCGT 1280
 PFDKHYLLADGTYYQTVA PLRVVHCQS N L R

Fig. 1A

2/10

GCATCAGATGTCATGCAATCTCTTCTTACGATGATCGCCTTGGTCATCTCGCCCAATTGGCCCTTCGGACATCCG 1360
 A S D V M D A I S S Y D D R L G H L A P F G L R D I R
 CAACACTGGTGATAATGGCTCTGCCCTCGATTTCCAAAGTGTCTTACTCGTCACCGATGCGCAGCCACGTAAACAATG 1440
 N T G D N G S A A C D F Q T V L L V T D G S H V N N
 GTATCAACGGTTTCCTCCAACAGATAACAGAGTCAAGCCATTTTCATGCCCTTGCAACAACCGTGCCCTCTCTGCACTGT 1520
 G I N G F L Q Q I T E S S H F M P C N N R A L L L H C
 CAGATGGAAGTAGCGGAGCTCTGCTGGTTGCCCTACTATGACCACAATGTTCGATTTCGATTGCTTCAGACAACGCGTCTGCT 1600
 Q M E S S G A L L V A Y Y D H N V I D S L Q T T R L L
 ACAGCAGTTTGGTCATCTGATCAAGTGTTCGAAAGTCTCTAGACCTGAGCTCTATGGCTGAGGTCAACTTGATGACTG 1680
 Q Q F G H L I K C L Q S P L D L S S M A E V N L M T
 AGTATGACAGACAGAGATTGAGAGTTGGAACCTCGCAACCGTTAGAGGTACAGGATACCCCTGATCCCATGAGATGTTG 1760
 E Y D R A E I E S W N S Q P L E V Q D T L I H H E M L
 AAAGCTGTTTCTCATTTCCCCACCAAAACGGCCATCCAAAGCGTGGATGGAGACTGGACCTATTTCAGTCTACTTTGAGAAGT 1840
 K A V S H S P T K T A I Q A W D G D W T Y S E L D N V
 TTCGTCAAGACTCGCTGCCATATCAAGTCACTTGGCCTTAGAGCTCAGCAAGCCATTATTCCAGTCTACTTTGAGAAGT 1920
 S S R L A V H I K S L G L R A Q Q A I I P V Y F E K
 CGAAATGGGTCAATGCTTCAATGCTGGTGTCTCAAGTCTGGTAATGCTTTCACCTCTAATTGATCCCAATGATCCACCA 2000
 S K W V I A S M L A V L K S G N A F T L I D P N D P P
 GCTCGAACTGCCAGGTGTCACGCAGACTCGGGCGACTGTAGCGCTTACTTCCAAAGCTACACCGCGAGACTGTACAGAA 2080
 A R T A Q V V T Q T R A T V A L T S K L H R E T V Q K
 GCTTGTAGGCCGTTGGTTGATGACGAGCTTCTGCAATCAGTTTCTGCCAGCGAGATTCTCAAGTCTGACCA 2160
 L V G R C V V V D D E L L Q S V S A S D D F S S L T
 AATCGCAAGACTTGGCCTACGTGATCTTCACTTCTGGTAGCACGGCGACCCGAAAGGCATCATGATTGAACACCGAGCG 2240
 K S Q D L A Y V I F T S G S T G D P K G I M I E H R A
 TTCTCATCATGTGCACTCAAGTTGGCGCGTCTCTTGGCATCAACTCTGATACTCGTGCCCTACAATTTGGAACCCATGC 2320
 F S S C A L K F G A S L G I N S D T R A L Q F G T H A
 CTTTGGCGCATGTCTTCTCGAGATTATGACTACTCTCATCAACGGTGGCTGGTTGTATTCCTCCGACGATGATCGTA 2400
 F G A C L L E I M T T L I N G G C V C I P S D D R
 TGAACAGTATCCCCGTCTTCATCAACCGATACAACGTTAATTGGATGGCGACACCTTCGTACATGGGAACCTTTTCA 2480
 M N S I P S F I N R Y N V N W M M A T P S Y M G T F S

Fig. 1B

3/10

CCTGAAGACGTTCTGGCCCTTGGACATTGGTACTTGTGGGAGCAGATGTCTATCTTCAAGCAATCTGGGCCCC 2560
 P E D V P G L A T L V L V G E Q M S S S V N A I W A P
 CAAGCTCCAACCTCTTGAACGGGTACGGACAGAGTGAAAGTTCTCAATTTGTTGGCTCCAATATGTCAACTGAGCCCA 2640
 K L Q L L N G Y G Q S E S S I C F A S N M S T E P
 ACAAATGGGACAGAGTCGGAGCTCATTTGATGGGTCAATTGACCCGACGATATAAACCGACTAGTTCGATTGGAGCT 2720
 N N M G R A V G A H S W V I D P N D I N R L V P I G A
 GTGGAGAACTGGTCAATTGAGAGTCCAGGCATTGCCCGGACTACATTGTTCCCCCCCCCTCCGGAGAGTCCCCATTCTT 2800
 V G E L V I E S P G I A R D Y I V P P P P E K S P F F
 CACAGACATTCGAAGCTGGTATCCAGCGAACACAGTTTCTGTGATGGGCAAACTCTACAGGACAGGAGATCTTGCAAGAT 2880
 T D I P S W Y P A N T F P D G A K L Y R T G D L A R
 ATGCCTCCGATGGTCCATCGTTTGCCTTGGGCGCATAGACTCGCAGGTCAAGATCCGGGGACAGCGTGTGAGCTGGGT 2960
 Y A S D G S I V C L G R I D S Q V K I R G Q R V E L G
 GCCATTGAGACCCATCTCCGACAGCAGATGCCAGACGACTTGACTATTGTGTAGAAAGCTACCAAGCGATCCCAATCTGC 3040
 A I E T H L R Q Q M P D D L T I V V E A T K R S Q S A
 CAACAGCACATCCTTAATTGCATTCTTAATAGGTCTTCTTACTTCGGAATAGACCCCTCGGATGCCACATTTCTGGACC 3120
 N S T S L I A F L I G S S Y F G N R P S D A H I L D
 ATGATGCTACCAAGCTATCAACATAAAGCTGGAGCAGGTATTGCTCGACACTCTATCCCTCATTCTACATCTGCATG 3200
 H D A T K A I N I K L E Q V L P R H S I P S F Y I C M
 CTGGAGCTTCCACGTACTGCCACCGGAAGATAGATAGGAGCGGACTACGAATCATGGGCAAGACATCTTGACAAGCA 3280
 L E L P R T A T G K I D R R R L R I M G K D I L D K Q
 GACCCAAAGGGCCATTGTTCAACAAGCACCCCGCTCCTATCCCTGTTTTCGACACACAGCAAGTCCACAGTATCT 3360
 T Q G A I V Q Q A P A P I P V F A D T A A K L H S I
 GGTACAGAGTTTGGGTATCGATCCAGCCACGGTCAATGTTGGGGCACTTTCTCGAACTCGGAGGAACTCTATCACT 3440
 W V Q S L G I D P A T V N V G A T F F E L G G N S I T
 GCTATCAAGATGGTGAACATGGCGAGGTCCGTTGGTATGGACCTCAAGGTCTCTAACATCTACCAGCACCCGCGTTGC 3520
 A I K M V N M A R S V G M D L K V S N I Y Q H P T L A
 GGGAATTTCCGGGTGTCAGGGTGATCCTCTGTCTACACTCTCATCCCCAAGTCAACTCATGAGGACCTGTTGAGC 3600
 G I S A V V K G D P L S Y T L I P K S T H E G P V E
 AGTCTTATTCACAAGGCCGACTATGTTCTCGATCAGTTGGACGTGTCGAGTCTGTGGTATCTGATTCATATGCTGTG 3680
 Q S Y S Q G R L W F L D Q L D V G S L W Y L I P Y A V

Fig. 1C

4/10

AGAAATGCGGGCGCTGTCAATGTGACGCGGTTACGTGGGCTCTTGACGCGCTTGAACAGCGACACGAGACTCTTAGAAC 3760
R M R G P V N V D A L R R A L A A L E Q R H E T L R T
GACATTTGAAGACCAGGATGGTGTGGGTGTACAAATTTTACGAGAAGCTTTCTGAGGAGATGAAGTCAATGATCTCT 3840
T F E D Q D G V G V Q I V H E K L S E E M K V I D L
GTGGTTCAGACCTTGAACCAAGAACAGACTACTCCCTTCAATCTCTCATCTGAAGCTGGCTGG 3920
C G S D L D P F E V L N Q E Q T T P F N L S S E A G W
AGAGCGACGCTCTTACGACTTGGTGAAGATGACCATCTCACTATTTGTCATCATCATCTCAGATGGTTGGTC 4000
R A T L L R L G E D D H I L T I V M H H I I S D G W S
AATTGATGCTTTCGACCGGATCTCAATCAGCTCTACTGCTGCGTCAAGGACTCAAAAGACCCGCTGTGAGCACTCA 4080
I D V L R R D L N Q L Y S A A L K D S K D P L S A L
CTCCTTACCTATCCAGTACAGCGACTTTTGCAAAATGGCAGAGGACCAATTCATAGAGGAGGAGCAACTCAACTAC 4160
T P L P I Q Y S D F A K W Q K D Q F I E Q E K Q L N Y
TGGAAGAAGCAACTCAAGACTCTTCCCCCAGCAAGATCCCGACCGACTTGGCCGCTGACCTTCTGTCTGGAGACGC 4240
W K K Q L K D S S P A K I P T D F A R P A L L S G D A
AGGTTGCGTACATGTACCATCGACGCGGAGCTCTACCAGTCCCTTCGAGCCTTCTGCAACGAAACACACGACCTCTT 4320
G C V H V T I D G E L Y Q S L R A F C N E H N T T S
TCGTGCTTCTTAGCTGGTTCGCTCGCTCATTTATCGTCTCACAGCTGTTGAAGACGCTGTCAATGGTACACCAATT 4400
F V V L L A A F R A A H Y R L T A V E D A V I G T P I
GCGAATCGCAACCGACCTGAACCTGGAGGATATCATCGGCTGCTTGTCAATACGCGAGTGTATGCGAATCAACATAGATCA 4480
A N R N R P E L E D I I G C F V N T Q C M R I N I D H
TCACGATACCTTTGGACTTTGATCAACCAAGTCAAGGCTACGACGACGAGCATTCGAGAACGAGGATATTCCTGTTG 4560
H D T F G T L I N Q V K A T T A A F E N E D I P F
AGCGGCTTGTATCAGCACTACAGCCTGGATCCAGAGATCTGTCAAGCACACCTCTCGCACAACTCATTTTTCAGTGCAC 4640
E R V V S A L Q P G S R D L S S T P L A Q L I F A V H
TCACAGAAGGACCTTGAAGATTCAAGTTCCAGGCTCTCGAGTCCGTACCTGTGCTAGCAAAAGCGTACACTCGATTGA 4720
S Q K D L G R F K F Q G L E S V P V P S K A Y T R F D
CATGGAGTTCCTGTTTCAAGAAACCGACAGCCTTAAAGGTAGCGTCAACTTTGCCGATGAGCTGTTCAAAATGGAGA 4800
M E F H L F Q E T D S L K G S V N F A D E L F K M E

Fig. 1D

5/10

CTGTTGAAAATGTCGTGAGAGTATTCTTTGAGATTCTGAGAAAACGGGCTTCAAAAGTTCCGGGACACCAAGTCTCAATACTT 4880
T V E N V V R V F F E I L R N G L Q S S R T P V S I L
CCTTTGACTGATGGCATTTGACTCTTGAAAAATTTGATGTTCTCAACGTCACCAATGTCGACTATCCCCGAGATCGAG 4960
P L T D G I V T L E K L D V L N V K H V D Y P R E S S
CTTGGCTGATGCTTCCAGACCCAAAGTCTCTGCTTACCCCGATAGTCTGGCTGTGGTGAGCTCCTCGTGCCGATTGACCT 5040
L A D V F Q T Q V S A Y P D S L A V V D S S C R L T
ACACCGAGTTGGATCGCCAGTCTGATATTCTCGCTGGATGGCTTCGTCGACGGTCAATGCCTGCAGAGACGCTTGTCCGA 5120
Y T E L D R Q S D I L A G W L R R R S M P A E T L V A
GTATTTGCCCCACGGTCATGTGAGACAATTGTGCGGTTCTTTGGTGTGTGAAGCGAACTTGGCCTATCTTCCCTCTCGA 5200
V F A P R S C E T I V A F F G V L K A N L A Y L P L D
TGTACGATCGCCCTCGGCGAGAGTTCAGGATATACCTTCTGAGCTTCTGGGCTTACCATTGTTTGTGATGGCCATGATA 5280
V R S P S A R V Q D I L S G L S G P T I V L I G H D
CAGCGCCTCCCGATATCGAGGTTACTAACGTGAGTTTGTTCGTATCCGGATGCGCTGAATGACAGCAATGCAGATGGC 5360
T A P P D I E V T N V E F V R I R D A L N D S N A D G
TTTGAAGTCATCGAGCAGCAGCACAAGCCCTCAGCCACGAGTCTCGCATACGTGCTGTATACCTCAGGATCCACTGG 5440
F E V I E H D S T K P S A T S L A Y V L Y T S G S T G
CCGACCAAAAGGCGTCATGATTGAGCACCGTGTCTATTTCGAACAGTCACAAGTGGCTGTATACCCAACTATCCTTCGG 5520
R P K G V M I E H R V I I R T V T S G C I P N Y P S
AAACGAGGATGGCTCACATGGCGACCAATTGCGTTTGACGGCGCATCGTACGAGATCTACAGCGCCCTTTTGTTCGGAAG 5600
E T R M A H M A T I A F D G A S Y E I Y S A L L F G R
ACACTTGTGCGTTGACTACATGACAACCCCTCGACGCTAGAGCACTCAAGGATGTGTTTTTCCGAGAGCATGTCAACGC 5680
T L V C V D Y M T T L D A R A L K D V F F R E H V N A
GGCAAGTCATGTCAACAGCTCTTCTCAAGATGTACCTCTCGAGTCCCGAGAAGGCTCTCGAGAACCCTTGATGTTCTTCT 5760
A S H V T S S S Q D V P L R V P R R L S R T L M F F
TCTTGGTGGTGACAGATTCCAGCGGCCCCAGATGCTCTCGATGCGCAGGACTTTATCAAGGGSTCCAGTGTACATGGT 5840
F L V V T D S T A P D A L D A Q G L Y Q G V Q C Y N G
TAGGGCCCAACAGAGATGGAGTCATGAGTACAATCTATCCCATGACTCGACTGAGTGGTTCATCAATGGAGTCCCAAT 5920
Y G P T E N G V M S T I Y P I D S T E S F I N G V P I

Fig. 1E

6/10

TGGACGAGCTCTGAACAACACTCAGGAGCGTATGTCTGGATCCTGAGCAACAGCTTGTGGCATTGGTGTGATGGGAGAGC 6000
 G R A L N N S G A Y V V D P E Q Q L V G I G V M G E
 TTGTTGTCACTGGCGATGGTCTTGGCGGGCTACAGTGACAAAGCCCTTGACGAGAACCGTTTGTGTCACATTACTGTGTC 6080
 L V V T G D G L A R G Y S D K A L D E N R F V H I T V
 AATGACCAGACAGTGAAGCGTATCGCACTGGCGATCGAGTGGCGGTACAGGATTGGAGATGGCCTCATCGAGTCTCTCGG 6160
 N D Q T V K A Y R T G D R V R Y R I G D G L I E F F G
 ACGTATGGACACCCAGTTCAAGATTCTGTGGCAATCGTATCGAATCAGTGAATGAAGCGGCCCTTCTGCGGACTCCT 6240
 R M D T Q F K I R G N R I E S A E I E A A L L R D S
 CCGTCCGAGATGCTGTCTGCTCTTCAGCAGAATGAGGATCAAGCGCCTGAGATCTTGGGTTTGTGTGCTGATCAT 6320
 S V R D A A V V L Q Q N E D Q A P E I L G F V V A D H
 GATCATTTGAGATGACAAGGGACAATCTGCCAATCAAGTCGAAGGATGGCAAGACCATTTCGAGAGTGGCATGTATTC 6400
 D H S E N D K G Q S A N Q V E G W Q D H F E S G M Y S
 CGACATTGGCGAAATTGACCCGTCGACGATTGGTAGCGACTTCAAGGGTTGGACATCAATGTATGATGAAGTCAAATCG 6480
 D I G E I D P S T I G S D F K G W T S M Y D G S Q I
 ACTTCGATGAGATGCACGAGTGGCTTGGTGAGACTACCCGGACACTCCATGACAATCGCTCTCTAGGCAATGTCTTGAA 6560
 D F D E M H E W L G E T T R T L H D N R S L G N V L E
 ATTGGAACAGGTAGCGGCATGATCCTCTTCAACCTTGACAGCAGGCTTGAGAGTTACGTTGGTCTTGAACCATCCAGATC 6640
 I G T G S G M I L F N L D S R L E S Y V G L E P S R S
 AGCAGCTGCATTTGTCAACAAGCTACCGAGTCTATACCATCGCTTGCTGGAAGCCAAAGTTTCAGGTGGACAGCTA 6720
 A A F V N K A T E S I P S L A G K A K V Q V G T A
 CAGATATTGGTCAAGTCGATGACTTACACCCCTGACCTCGTGTCTCAACTCAGTCATTTCAGTATTTCCTCGGAG 6800
 T D I G Q V D D L H P D L V V L N S V I Q Y F P S S E
 TACCTTGCAGAAATCGCAGACACCTTGATTTCATCTGCCCTAACGTGCAGCGGATTTTCTTTGGCGATGTCCGATCGCAGGC 6880
 Y L A E I A D T L I H L P N V Q R I F F G D V R S Q A
 CACCAACGAGCACTTCTTGTGCCAGGGCTATCCACACACTGGGGAAGAATGCAACGAAGGACGATGTTGACAGAAAA 6960
 T N E H F L A A R A I H T L G K N A T K D D V R Q K
 TGGCAGAATTGGAGGACATGGAGGAGGAGTGTGTTGAACCTGCTTTCACCTCGTTGAAAGACAGGTTTCCAGGT 7040
 M A E L E D M E E L L V E P A F F T S L K D R F P G
 CTGGTGAACATGTTGAGATCCTGCGCAAGAACATGGAAGCTGTGAATGAGCTCAGTGCATCGATATGCCGCTGTGT 7120
 L V E H V E I L P K N M E A V N E L S A Y R Y A A V V

Fig. 1F

7/10

GCACGTTCCGGGTTCACTTGGAGATGAGCTTGTGCTTCCGGTTGAGAAAGATGACTGGATCGACTTTCAGCGGAATCAAT 7200
 H V R G S L G D E L V L P V E K D D W I D F Q A N Q
 TGAACGAGAAGTCACTGGGTGACCTTCTCAAGTCTCAGATGCTGTATCATGGCAGTCAGCAAAATTCCTTTCGAAATC 7280
 L N Q K S L G D L L K S S D A A I M A V S K I P F E I
 ACGGCCTTTGAAAGACAGGTGCTGCTTCCCTCAATAGCAACATCGATGAGTGGCAGCTATCAACCATTCGGTCCAGCGC 7360
 T A F E R Q V V A S L N S N I D E W Q L S T I R S S A
 CGAGGCGCACTCATCACTATCCGTTCCCGACATCTTTCGGCATGTGCGGAAGCCGGGTTCCGTGTGAGGTCAGTTCTG 7440
 E G D S S L S V P D I F R I A G E A G F R V E V S S
 CACGACAGTGGTCTCAGAATGGTGCAATGGACGCTGTTTCCATCATGTTGCTCCCAAGGCGTACTCTGGTCAACTTT 7520
 A R Q W S Q N G A L D A V F H H C C S Q G R T L V N F
 CCTACGGACCATCACCTTCGAGGGTCTGATCTCCTCACCAATCGACCCCTTCAGCGACTGCAAAACCGTCTGTATCGCCAT 7600
 P T D H H L R G S D L L T N R P L Q R L Q N R R I A I
 CGAAGTCCGCGAGAGGCTTCGGTCTTACTTCCATCGTACATGCCATCGAACATCGTTGTTCTGGACAAGATGCCTC 7680
 E V R E R L R S L L P S Y M I P S N I V V L D K M P
 TCAACGCCAATGGTAAAGTTGACCGGAAGGAACCTCTCTCGCAGGGCAAAAGTTGTACCGAAGCAGCAGACAGCGGCCG 7760
 L N A N G K V D R K E L S R R A K V V P K Q Q T A A P
 TTACCGACATTTCCCATCAGTGAGGTGCAAGTCAATCTTTGCGAAGAACCCACTGAGGTGTTTGGCATGAAGTTGACAT 7840
 L P T F P I S E V E V I L C E E A T E V F G M K V D I
 TACCGATCACTTCTTCAATCTCGGTGGACACTCTCTTGGCCACGAAAGCTCATTTCTCGTATCGACCAACGACTCAAGG 7920
 T D H F F N L G G H S L L A T K L I S R I D Q R L K
 TCCGTATCACTGTCAAGGATGTCTTTGACCATCTGTATTTGCGGATCTAGCATCTGTATCCGTCAAGGCTGGGTTG 8000
 V R I T V K D V F D H P V F A D L A S V I R Q G L G L
 CAACAACCCGTTTCTGATGGTCAGGACAAGACAGATCTGCCACATGGCACCCCGTACCGAGACTGAAGCTATACTCTG 8080
 Q Q P V S D G Q G Q D R S A H M A P R T E T E A I L C
 TGATGAGTTTGCAAGGTTCTGGGGTTCCAGTGGGATTACAGACAATTTCTTTGATCTTGGTGGTCAATTCACATCGG 8160
 D E F A K V L G F Q V G I T D N F F D L G G H S L M
 CTACTAAACTCGCTGCGCATCGGACATCGACTTGACACGACTGTTTCGGTGAAGGATGTTTTCGATCATCTGTACTC 8240
 A T K L A V R I G H R L D T T V S V K D V F D H P V L
 TTCCAACCTTGCAATTGGATAACTTGGTTCAATCCAGACCAATGAGATAGTGGAGGTAGAGAAATGGCTGAATA 8320
 F Q L A I A L D N L V Q S K T N E I V G G R E M A E Y

Fig. 1G

8/10

CTCACCTTTCCAACTCCTCTTTACAGAAGACCCAGAGGAGTTTATGGCGAGCGAGATCAAGCCACAACCTTGAGTTACAGG 8400
 S P F Q L L F T E D P E E F M A S E I K P Q L E L Q
 AAATCATTTCAAGACATATATCGGTCTACCCAGATGCAGAAGGCTTTCCTCTTCGATCACAACAACCTGCGGCCCGAGACCT 8480
 E I I Q D I Y P S T Q M Q K A F L F D H T T A R P R P
 TTCGTGCGCTTCTACATCGACTTCCCGAGCACTTCCGAGCCTGATGCTGAGGTCTAATCAAGGCTTTCGAGTCTCTGGT 8560
 F V P F Y I D F P S T S E P D A A G L I K A C E S L V
 AAATCATCTTGACATCTTCAGAACAGTCTTTGCAGAGGCATCTGGAGAACTATACCAAGTGGTCTTGCTCTGTGATC 8640
 N H L D I F R T V F A E A S G E L Y Q V V L S C L D
 TGCCAAATCCAAGTGTGAGACAGAGACAACATCAATACGGCGACAATGAGTTTCTCGATGAGTTTGCAGAAAGAGCCA 8720
 L P I Q V I E T E D N I N T A T N E F L D E F A K E P
 GTTCGTCTGGGACATCCGTTGATTCGTTTACAAATCATCAAAACAACCAAGTCGATGCGTGTGATAATGAGAATATCGCA 8800
 V R L G H P L I R F T I I K Q T K S M R V I M R I S H
 TGCCCTGTATGATGGTCTGAGTCTAGAGCATGTCTGCGCAAACTTCACATGCTCTACAAACGGGAGATCACTTTTGCCAC 8880
 A L Y D G L S L E H V V R K L H M L Y N G R S L L P
 CACACCAATTTCTCGGGTACATGCAGTATACTGCTGACGGTCGCGAAAGTGGACATGATTTTGGCGCGATGTGATTCAA 8960
 P H Q F S R Y M Q Y T A D G R E S G H G F W R D V I Q
 AATACGCCCATGACAATATTGAGTGATGACACGGTTGTGTGATGGAATGATGCAACCTGCAAGGCGTTGCACCTATCAA 9040
 N T P M T I L S D D T V V D G N D A T C K A L H L S K
 GATTGTCAATATTCCTTCACAGGTACTTCGAGGCGAGCAGTAACATCACTACTCAAGCTACTGTGTAAACGCGCCTGCG 9120
 I V N I P S Q V L R G S S N I I T Q A T V F N A A C
 CGTTAGTCTTGTCACGGGAATCTGACTCGAAAGACGTTGTCTTTGGACGCATCGTCTCTGTCGTCGTCAGGCTTGCCCTGTT 9200
 A L V L S R E S D S K D V V F G R I V S G R Q G L P V
 GAATACAGGACATTTGCGGCCCTTGTAACCAACGAGTTCTCTGCGCTCATATAGAGTCGTCAGATTACAACCAATT 9280
 E Y Q D I V G P C T N A V P V R A H I E S S D Y N Q L
 GCTGCACGACATCCAAGACCAAGTACCTTCTCAGCTTGCCACACGAAACAATTTGGCTTCTCAGATCTCAAGCGCAACTGTA 9360
 L H D I Q D Q Y L L S L P H E T I G F S D L K R N C
 CAGATTGGCCAGAGCAATCAACCACTTCTCATGTGTCATCACATACCACAATTTTCGAGTACCATCCCGAGAGTCAGTTC 9440
 T D W P E A I T N F S C C I T Y H N F E Y H P E S Q F
 GAACAGCAGAGATTGAGATGGGTGATTGACAAAGTTTGTCAACATGAGATGGATGAGCCACTATATGATTTGGCGAT 9520
 E Q Q R R V E M G V L T K F V N I E M D E P L Y D L A I

Fig. 1H

9/10

TGCGGGTGAAGTTGAACCCAGACGGAGCAGGACTGAAGGTTACTGTTATCGCGAAGACGCAGTTATTGGTAGGAAGAGAG 9600
A G E V E P D G A G L K V T V I A K T Q L F G R K R
TAGAACATCTGTTGGAGGAAGTTTCCAAAACGTTTGGGGTCTCAACTCTTCTTGTAAACGCACGGGTTGGTCTCAATCG 9680
V E H L L E E V S K T F E G L N S S L
TCGGACAGAACCAACCGATGTAGGTTTGTAAATCTTAAATGACGCTTTTGACTTTTGGTTTTTACCATTTCGGAGCAATA 9760
GTAAGCAGAACACTGGCAATGTCCAGATATTACACTTCAGAACTATTATCTTGACTATTATCTCAGTTGTTCAGCTTTTCA 9840
CATGCTTGCTACGTTTCGATCGAGTCAAAAATTGAGATCTACAGGTAACGCAGGAATCCAGAACAAATTGACAAGGATTCA 9920
TCGATCGAACACATAATGATTGGTTTCGGCTCTCTGACAGGACCAATTTGTCCAATAATAGAAGTATAGATAAGATATGCGAGG 10000
AATGCGACAAGGATTGGAACCTATCCGAGTCAGCTTGATCTAGTCCCTAAACAGTAAATAGCTCGCGCTTCTTCGGATTTCG 10080
CTTTGGTGTATGAATTATCATAGTTTGTGTCGAAAGAACAAATACCTTGACAATATTGTGTTCCAACATTACACAACACTTGA 10160
ATAAAGGTATGACTCTTGATATGATCAAAATTAGAAACAAATAGAAATGATGTTTCAACATTACACAACACTTGA 10240
ACGGGACACTCYTTCAACATCAACACAAATGGATCTGTCCAAACAAAGCTGCCTACCTTGTCAAGTCCCAATGGGCCCACT 10320
CGAAGTCAGATCTGCACCTGTTCCAAACACTGTTTCAGGAGGTTGCTTATCAAGACACATGCTGTGCGCATCAATCCAG 10400
TCGACGGAGTGAAGCAGTCCATGGGTAAACATGATGTTTGAATGGCTCAAGTATCCTCTCATCCTTGGCTACGATGTCGCT 10480
GGCGAGGTCAACAAGACGGACCTGGTGTAGTCGATTTAAAGAGGCGATAGATTGTGGTGTCTACAGCAGGCGATGGA 10560
CAAGCGAGGAAGAAGTCCCGACGAAGCGCATTTCAAGAAAGTTTGCATCATGCGAGAGCATTTGGTGTCTCGAATTCAG 10640
AGCGTGTACGTCCACCGATGCCAGCGTTTTCCTCTGACTTTTCGTACCGCTGCATGTGCCTTGTTCCTCAAAAGGATCAA 10720
CTGGCACTACAACCTACCTCAACCAAGTCAAGCGCAGTGCACCAAGTCAGACAGTCTTGGTTTGGGAGCGAGTACAAG 10800
TGTTGGGAGAAATGCTGTACAGCTTGTGTCGGCGGCTATGATGTTGTGCGGACAGCATCACCTAAGAACTGGGATA 10880
TCGTACGGGCTCTCGGCGCTTGTGAGTTTGTGACTATCAGAGTCACTGGGCAATGCGTCGACATGTCGATGTTTCAAG 10960
GACAAAGAAATGCGCAGGTGCTGTAGCTATTGGTCAAGGTCACCTGGCGAAATGCGTCGACATTGTCAAAGCGTTCCGGG 11040
AGCCACCAAGAAATGTTGCGCAAGTTACCTCTCAATGCTGAGTCAACAGCCCAACCAAGATATCCATGATTCGGTTTG 11120
TCGCAAGATTTCTGGATGGCGGGAACCTGATCGACTCAAGGTTGCGAGCGAGTGGAGTCCAAAGCAAGTTTGTTTTGGT 11200
ACAGACATAATT 11212

Fig. 11

10/10




Fig. 2

SEQUENCE LISTING

<110> Randy M. Berka
Michael W. Rey
Wendy T. Yoder

<120> Methods For Producing Polypeptides In
Cyclohexadepsipeptide-Deficient Cells

<130> 5778.204-WO

<140> To Be Assigned

<141> 2000-01-13

<150> 09/229,862

<151> 1999-01-13

<160> 4

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 11212

<212> DNA

<213> Fusarium

<400> 1

aattagattc	cactagtacg	ccattgtaga	atcaaggcca	agatatgaac	aaccataag	60
taacggcgat	cctgtctcat	gtatccaaaa	ataagagaca	cggcatattc	actgctttgc	120
agatctttct	tcaaattctct	ccctcgagaa	gctactggga	tgaatgagtc	tcttggtcca	180
gattagatat	attcactgta	tctgccgaat	agactttgcc	tggtagcatt	aacgttccta	240
tattctatta	tcaaattcctt	acattcaata	tggaaatatct	tactgctgtc	gatggtaggc	300
aagacctgcc	acctacacca	gcttcgtttt	gtagtcatgg	agatagtcct	ctcaatagct	360
cttacgagca	actcttccat	ctctatgggc	tggattcgag	tcgcatcgaa	gctatcaaac	420
catgcacacc	tttccagctt	gacatgatcg	actgcaatgc	tttggataag	cagtctgcta	480
tcggccatgc	ggtgtatgat	gtcccaaccg	acattgacat	ctctcgtttc	gcgcttgctg	540
ggaaggagat	cgtcaaccaa	acccagcctt	tgcgagcctt	tgcttccacc	tcggactctg	600
gaaagacttc	tcaagtcata	ctaaaagata	gctttgtctt	ctcatggatg	tgctggctct	660
cttcgagctc	cccagatgaa	gtgggttcggg	atgaagctgc	cgctgctgca	tccggggccac	720
gctgcaaccg	cttcgttcta	cttgaagaca	tgcagacgaa	gaaatgtcag	ctgggtttgga	780
ccttcagtca	tgcattggta	gacgtcactt	tccaacaacg	cgctcctgagc	cgtgttttcg	840
cggcttacaa	gcatgagaag	gacacacatc	ggcctgagac	acccgagtca	tctgatgcca	900
ctgacactga	ctctcagtca	gtctccgtgg	tgtccatgag	ctgcgaggac	aatgccgtat	960
cggcgactca	tttctggcaa	actcacctta	acgatctcaa	tgcgtccgct	ttccctcacc	1020
tgtctgacca	cctgatgggtg	cccaacccaa	ctacaacagc	agagcatcgt	atcacattcc	1080
ctctttcaca	gaaagcacta	tccaattctg	ccatctgccc	tactgcactc	tcaatactcc	1140
tctcgcgcta	cactcactct	gacgaggcct	tgtttgggtg	ggtaactgag	caatctctac	1200
catttgacaa	acactatctt	gcagatggta	cgtaccaaac	agttgcaccc	cttcgtgtac	1260
actgccaatc	aaatcttctg	gcatcagatg	tcatggatgc	aatctcttct	tacgatgatc	1320
gccttggtca	tctcgcccca	tttggccttc	gcgacatccg	caacactggt	gataatggct	1380
ctgcgcctg	cgatttccaa	actgttttac	tcgtcaccga	tggcagccac	gtaaacaatg	1440
gtatcaacgg	tttcctccaa	cagataaacg	agtcaagcca	tttcatgcct	tgcaacaacc	1500
gtgccctcct	tctgcactgt	cagatggaaa	gtagcggagc	tctgctggtt	gcctactatg	1560
accacaatgt	tatcgattcg	cttcagacaa	cgcgtctgct	acagcagttt	ggatcatctga	1620
tcaagtgttt	gcaaagtcc	ctagacctga	gctctatggc	tgaggtcaac	ttgatgactg	1680
agtatgacag	agcagagatt	gagagttgga	actcgcaacc	gttagaggta	caggataccc	1740

tgatccacca	tgagatgttg	aaagctgttt	ctcattcccc	cacaaaaacg	gccatccaag	1800
cgtgggatgg	agactggacc	tattccgagc	tcgacaatgt	ttcgtcaaga	ctcgctgtcc	1860
atatcaagtc	acttggcctt	agagctcagc	aagccattat	tccagtctac	tttgagaagt	1920
cgaaatgggt	cattgcttca	atgctggctg	ttctcaagtc	tggtaatgct	ttcactctaa	1980
ttgatcccaa	tgatccacca	gctcgaactg	cccaggctcg	cacgcagact	cgggcgactg	2040
tagcgcttac	ttccaagcta	caccgcgaga	ctgtacagaa	gcttgtaggc	cgttgcgttg	2100
tggttgatga	cgagcttctg	caatcagttt	cttgccagcga	cgatttctca	agtctgacca	2160
aatcgcaaga	cttggcctac	gtgatcttca	cttctggtag	cacgggcgac	ccgaaaggca	2220
tcatgattga	acaccgagcg	ttctcatcat	gtgcactcaa	gttcggcgcg	tctcttgcca	2280
tcaactctga	tactcgtgcc	ctacaatttg	gaacccatgc	ctttggcgca	tgtcttctcg	2340
agattatgac	tactctcatc	aacgggtggct	gcgtttgtat	tccctccgac	gatgatcgta	2400
tgaacagtat	cccgtccttc	atcaaccgat	acaacgttaa	ttggatgatg	gcgacacctt	2460
cgtaacatggg	aaccttttca	cctgaagacg	tctctggcct	tgcgacattg	gtacttgttg	2520
gggagcagat	gtcatcttca	gtcaacgcaa	tctgggcccc	caagctccaa	ctcttgaacg	2580
ggtacggaca	gagtgaaggt	tcctcaattt	gttttgcttc	caatatgtca	actgagccca	2640
acaacatggg	cagagcagtc	ggagctcatt	catgggtcat	tgaccggaac	gatataaacc	2700
gactagttcc	gattggagct	gtgggagaac	tggtcattga	gagtcagggc	attgcccgcg	2760
actacattgt	ccccccctt	ccggagaagt	ccccattctt	cacagacatt	ccaagctggg	2820
atccagcgaa	cagcttttct	gatggggcaa	aacctcacag	gacaggagat	cttgcaagat	2880
atgcctccga	tggttccatc	gtttgccttg	ggcgcataga	ctcgcaggtc	aagatccggg	2940
gacagcgtgt	tgagctgggt	gccattgaga	cccattctcc	acagcagatg	ccagacgact	3000
tgactattgt	ggtagaagct	accaagcgat	cccaatctgc	caacagcaca	tccttaattg	3060
cattcctaatt	aggttcttct	tacttcggaa	atagaccctc	ggatgcccac	attctggacc	3120
atgatgctac	caaagctatc	aacataaagc	tggagcaggt	attgcctcga	cactctatcc	3180
cctcattctta	catctgcatt	ctggagcttc	cagctactgc	caccgggaag	atagatagga	3240
ggcgactacg	aatcatgggc	aaagacatct	tggacaagca	gacccaaggg	gccattgttc	3300
aacaagcacc	cgctcctatc	cctgttttct	cagacacagc	agcaaagctc	cacagtatct	3360
gggtacagag	tttgggtatc	gatccagcca	cggccaatgt	tggggcaact	ttcttcgaac	3420
tcggaggaaa	ctctatcact	gctatcaaga	tggtgaacat	ggcgagggtc	gttgggtatg	3480
acctcaaggt	ctctaactc	taccagcacc	cgaagcttgc	gggaatttcc	gcggctcgta	3540
aggttgatcc	tctgtcctac	actctcatcc	ccaagtcaac	tcatgaggga	cctgttgagc	3600
agtcttatcc	acaaggccga	ctatggttcc	tggatcagtt	ggacgttggc	agtctgtggt	3660
atctgattcc	atatgctgtg	agaatgcgcg	ggcctgtcaa	tgtcgacgcg	ttacgtcggg	3720
ctcttgacgc	gcttgaacag	cgacacgaga	ctcttagaac	gacatttgaa	gaccaggatg	3780
gtgtcggtgt	acaaattgtt	cacgagaagc	tttctgagga	gatgaagggt	attgatctct	3840
gtggttcaga	accttgaccg	tttgaggtgt	tgaaccaaga	acagactact	cccttcaatc	3900
tctcatctga	agctggctgg	agagcgacgc	tcttacgact	tggtgaagat	gaccacatcc	3960
tcactattgt	catgcatcac	atcatctcag	atggttgggt	aattgatgtc	ttgcgacgcg	4020
atctcaatca	gctctactca	gctgcgctca	aggactcaaa	agaccgctg	tcagcactca	4080
ctcctctacc	tatccagtac	agcgactttg	caaaatggca	gaaggaccaa	ttcatagagc	4140
aggagaagca	actcaactac	tggagaagac	aactcaaaga	ctcttcccca	gcaaagatcc	4200
cgaccgactt	tgcccgccct	gcacttctgt	ctggagacgc	aggttgcgta	catgtttacca	4260
tcgacggcga	gctctaccag	tcccttcgag	ccttctgcaa	cgaacacaac	acgacctctt	4320
tcgtcgttct	tctagctgcg	ttccgtgccg	ctcattatcg	tctcacagct	gttgaagacg	4380
ctgtcattgg	tacaccaatt	gcgaatcgca	accgacctga	actggaggat	atcatcggtc	4440
gctttgtcaa	tacgcagtgt	atgcgaatca	acatagatca	tcacgatacc	tttgggactt	4500
tgatcaacca	agtcaaggct	acgacgacag	cagcattcga	gaacgaggat	attccgtttg	4560
agcgcgttgt	atcagcacta	cagcctggat	ccagagatct	gtcaagcaca	cctctcgcac	4620
aactcatttt	tgcagtgcac	tcacagaagg	accttgggaag	attcaagttc	cagggtctcg	4680
agtccgtacc	tgtgcctagc	aaagcgtaca	ctcgatttga	catggagtgc	catctgtttc	4740
aagaaaccga	cagccttaaa	ggtagcgtca	actttgccga	tgagctgttc	aaaatggaga	4800
ctggtgaaaa	tgtcgtcaga	gtattctttg	agattctgag	aaacgggctt	caaagtctcg	4860
ggacaccagt	ctcaatactt	cctttgactg	atggcattgt	gactcttgaa	aaattggatg	4920
ttctcaacgt	caaacatgtc	gactatcccc	gagaaatcgag	cttggctgat	gtcttccaga	4980
cccaagtctc	tgttaccctc	gatagtctgg	ctgtggtgga	ctcctcgtgc	cgattgacct	5040
acaccgagtt	ggatcgccag	tctgatattc	tcgctggatg	gcttcgtcga	cgggtcaatgc	5100
ctgcagagac	gcttgtcgca	gtatttgccc	cacggtcatg	tgagacaatt	gtcgcgttct	5160
ttggtgtgtt	gaaggcgaa	ttggcctatc	ttcctctcga	tgtacgatcg	ccctcgcgca	5220

gagttcagga	tatactttct	ggactttctg	ggcctaccat	tgttttgatt	ggccatgata	5280
cagcgctcc	cgatatcgag	gttactaacg	tcgagtttgt	tcgtatccgg	gatgcgctga	5340
atgacagcaa	tgcagatggc	tttgaagtca	tcgagcacga	cagcacaaag	ccctcagcca	5400
cgagtctcgc	atacgtgctg	tatacctcag	gatccactgg	ccgacaaaaa	ggcgatcatga	5460
ttgagcaccg	tgctcattatt	cgaacagtca	caagtggctg	tatacccaac	tatccttcgg	5520
aaacgaggat	ggctcacatg	gcgaccattg	cgtttgacgg	cgcatcgta	gagatctaca	5580
gcgccccttt	gttcggaagg	acacttggtt	gcgttgacta	catgacaacc	ctcgacgcta	5640
gagcactcaa	ggatgtgttt	ttccgagagc	gtacacagc	ggcaagtcac	gtcaccagct	5700
cttctcaaga	tgtacctctc	cgagtcctcg	gaaggctctc	gagaaccttg	atgttcttct	5760
tcttggtggt	gacagattcg	acggccccag	atgctctcga	tgcgagggga	ctttatcaag	5820
gggtccagtg	ttacaatggt	tacggcccaa	cagagaatgg	agtcagagtg	acaatctatc	5880
ccattgactc	gactgagtcg	ttcatcaatg	gagtcaccaat	tggacgagct	ctgaacaact	5940
caggagcgta	gtcgtggat	ctgagcaac	agcttggttg	cattggtgtg	atgggagagc	6000
ttgttgctac	tggcgatggt	cttgcgctgg	ctgacagtga	caaagccctt	gacgagaacc	6060
gttttggtgca	cattactgtc	aatgaccaga	cagtgaaggc	gtatcgact	ggcgatcgag	6120
tgcggtacag	gattggagat	ggcctcatcg	agttcttcgg	acgtatggac	acccagttca	6180
agattcgtgg	caatcgtatc	gaatcagctg	agattgaagc	ggcccttctg	cgcgactcct	6240
ccgtccgaga	tgctgctgtc	gtccttcagc	agaatgagga	tcaagcgcct	gagatcttgg	6300
ggtttggtgtg	tgctgatcat	gatcattctg	agaatgacaa	gggacaatct	gccaatcaag	6360
tcgaaggatg	gcaagaccat	ttcgagagtg	gcattgtattc	cgacattggc	gaaattgacc	6420
cgctcgacgat	tggtagcgac	ttcaagggtt	ggacatcaat	gtatgatgga	agtcaaactc	6480
acttcgatga	gatgcacgag	tggcttggtg	agactaccgc	gacactccat	gacaatcgct	6540
ctctaggcaa	tgctcctgaa	attggaacag	gtagcggcat	gatcctcttc	aaccttgaca	6600
gcaggcttga	gagttacgtt	ggcttgtaac	catccagatc	agcagctgca	tttgtcaaca	6660
aagctaccga	gtctatacca	tcgcttgctg	gaaaagccaa	ggttcaggtt	ggaacagcta	6720
cagatattgg	tcaagtcgat	gacttacacc	ctgacctcgt	ggttctcaac	tcagtcattc	6780
agtatttccc	gtcttcggag	taccttgacg	aaatcgaga	caccttgatt	catctgccta	6840
acgtgcagcg	gattttcttt	ggcgatgtcc	gatcgagggc	caccaacgag	cacttccttg	6900
ctgccagggc	tatccacaca	ctggggaaga	atgcaacgaa	ggacgatgtt	cgacagaaaa	6960
tggcagaatt	ggaggacatg	gaggaggagt	tgcttggtga	acctgcttcc	ttcacctcgt	7020
tgaagacag	gtttccagg	ctggtggaac	atggtgagat	cctgccaag	aacatggaag	7080
ctgtgaatga	gctcagtgcg	tatcgatatg	ccgtgtgtgt	gcacgttcgg	ggttcacttg	7140
gagatgagct	tgtgcttccg	gttgagaaag	atgactggat	cgactttcaa	gcgaatcaat	7200
tgaaccagaa	gtcactgggt	gaccttctca	agtcttcaga	tgctgctatc	atggcagtea	7260
gcaaaattcc	tttcgaaatc	acggcctttg	aaagacaggt	cgctcgctcc	ctcaatagca	7320
acatctatga	gtggcagcta	tcaaccattc	ggctccagcg	cgaggggcag	tcactactat	7380
ccgttcccg	catctttcgc	attgctgggg	aagccgggtt	ccgtgtcgag	gtcagttctg	7440
cacgacagtg	gtctcagaat	ggtgcattgg	acgctgtttt	ccatcattgt	tgctcccaag	7500
ggcgactact	ggtcaacttt	cctacggacc	atcaccttcg	agggtctgat	ctcctcacca	7560
atcgacccct	tcagcgactg	caaaaccgtc	gtatcgccat	cgaagtcgcg	gagaggcttc	7620
ggtccttact	tccatcgta	atgatcccat	cgaacatcgt	tggtctggac	aagatgcctc	7680
tcaacgcca	tggtaaagtt	gaccggaagg	aactctctcg	caggggcaaag	gttgtaccga	7740
agcagcagac	agcagcgccg	ttaccgacat	ttcccatcag	tgaggtcgaa	gtcattcttt	7800
gcgaagaagc	cactgaggtg	tttggcatga	agggtgacat	taccgatcac	ttcttcaatc	7860
tcggtggaca	ctctctcttg	gccacgaagc	tcatttctcg	tatcgaccaa	cgactcaagg	7920
tccgtatcac	tgtaaggat	gtctttgacc	atcctgtatt	tgcgatctta	gcactctgtca	7980
tccgtcaagg	gctgggtttg	caacaaccgc	tttctgatgg	tcagggacaa	gacagatctg	8040
cccacatggc	acccgtacc	gagactgaag	ctatactctg	tgatgagttt	gcaaagggtc	8100
tggggttcca	agtcgggatt	acagacaatt	cttttgatct	tggtggtcat	tcactcatgg	8160
ctactaaact	cgctgtgcgc	atcgacatc	gacttgacac	gactgtttcg	gtgaaggatg	8220
ttttcgatca	tcctgtactc	ttccaacttg	caattgcatt	ggataacttg	gttcaatcca	8280
agaccaatga	gatagttgga	ggttagagaaa	tggctgaata	ctcacctttc	caactcctct	8340
ttacagaaga	cccagaggag	tttatggcga	gcgagatcaa	gccacaactt	gagttacagg	8400
aaatcattca	agacatatat	ccgtctaccc	agatgcagaa	ggctttctct	ttcgatcaca	8460
caactgcgcg	cccagacact	ttcgtgccgt	ttcacatcga	cttccccagc	acttccgagc	8520
ctgatgctgc	aggtctaatc	aaggcttgcg	agtctctggt	aaatcatctt	gacatcttca	8580
gaacagtctt	tgagaggca	tctggagaac	tataccaagt	ggcttctgtc	tgctctgatc	8640
tgccaatcca	agtgattgag	acagaagaca	acatcaatac	ggcgacaaat	gagtttctcg	8700

```

atgagtttgc gaaagagcca gtctgtctgg gacatccgtt gattcgtttt acaatcatca 8760
aacaaccaca gtcgatgcgt gtgataatga gaatatcgca tgccctgtat gatggctcga 8820
gtctagagca tgctgtgcgc aaacttcaca tgctctacaa cgggagatca cttttgccac 8880
cacaccaatt ctgcgcgtac atgcagtata ctgctgacgg tcgcgaaagt ggacatggat 8940
tttggcgcga tgtgattcaa aatacgccca tgacaatatt gagtgatgac acggttgttg 9000
atggaaatga tgcaacctgc aaggcgttgc acctatcaaa gattgtcaat attccttcac 9060
aggtacttcg aggcagcagt aacatcatta ctcaagctac tgtgtttaac gcagcctgcg 9120
cgtagtctt gtcacgggaa tctgactcga aagacgttgt ctttggacgc atcgtctctg 9180
gtcgtcaagg cttgcctgtt gaataccagg acattgtcgg gccttgtacc aacgcagttc 9240
ctgttcgcgc tcatatagag tcgtcagatt acaaccaatt gctgcacgac atccaagacc 9300
agtaccttct cagcttgcca cacgaaacaa ttggcttctc agatctcaag cgcaactgta 9360
cagattggcc agaagcaatc accaacttct catgctgcat cacataccac aatttcgagt 9420
accatcccca gagtcagttc gaacagcaga gagttgagat ggggtgattg acaaagtttg 9480
tcaacattga gatggatgag ccaactatag atttggcgat tgcgggtgaa gttgaaccag 9540
acggagcagg actgaagggt actgttatcg cgaagacgca gttatttggg aggaagagag 9600
tagaacatct gttggaggaa gtttccaaaa cgtttgaggg tctcaactct tctttgtaac 9660
gcacgggttg gtctcaatcg tcgcgacaga acaaccgatg taggtttgta attcttaatg 9720
acgtctttga ctttttgggt tttaccattc ggagcaaata gtaagcagaa cactggcaaa 9780
tgtcagatat tacacttcag aactattatc ttgactatta tctcacgttg tcagctttca 9840
catgcttgct acgttcgacg gagtcaaaaa ttgagatcta cagggttaacg caggaaatcca 9900
gaacaattga caaggattca tcgatcgaac actatgattg gttcgcgtct ctgacaggac 9960
catttgcca ataatagaag tatagataag atatgcgagg aatgcgacaa ggattggaac 10020
tatccgagtc agcttgatct agtccctaaa cagtaaatag ctgcgcgttc ttcggattcg 10080
ctttgggtga tgaattatca tagtttgttg tgcaagaag aacgatgatg acagcttgta 10140
ttttggatat atataagttc ataaagggtat gactcttgat atgatcaaat tagaaacaat 10200
accttgacaa tattgtgttc caacattaca caacacttga acgggacact cyttcaacat 10260
caacacaatg gatctgtcca acaaagctgc ctacctgtc agtcccaatg ggcccaccat 10320
cgaagtcaaga tctgcacctg ttccaacacc tgggtcagga gagttgctta tcaagacaca 10380
tgctgtcgcc atcaatccag tcgacggagt gaagcagtc atgggtaaca tgatgtttga 10440
atggctcaag tatcctctca tccttgggta cgatgtcgct ggcgaggtea tcaagacggg 10500
acctgggtgt agtcgattta aagaaggcga tagagttgtg ggtgctacag caggcatgga 10560
caagcgagga agaagtcctc acgaaggcgc atttcaagaa gtttgcata tgcgagagca 10620
tttggctgct cgaattccag agcgtgttac gtccaccgat gccagcgttt tgcctctgac 10680
tttctgcacg gctgcatgtg ccttgttcca aaaggatcaa ctggcactac aactacctca 10740
aaccaagtca aagcgcagtg caacaagtca gacagtcttg gtttggggag cgagtacaag 10800
tgttgggaga aatgctgtac agcttgtgtg cgcggccggc tatgatgttg tcgcgacagc 10860
atcacctaag aactgggata tcgtacgcgg tctcggcgct tgtgcagttt ttgactatca 10920
cagctcatcg gccataaacg atgtggtatc tgctttcaag gacaagaaat gcgcaggtgc 10980
tgtagctatt ggtcaagggt cactggcgaa atgcgtcgac attgtcaaaa gcgttccggg 11040
agccaccaag aatgttgccg aagttaccct ctcaatgcct gagtcacagc caacaaccaa 11100
gatatccatg attccggttg tcgcaaagta tttctggatg gcgggaactg atcgactcaa 11160
ggttgcgagc agtgaggtcc aaagcaagtt tgttttgggt acagacataa tt 11212

```

<210> 2
 <211> 3129
 <212> PRT
 <213> Fusarium

<400> 2
 Met Glu Tyr Leu Thr Ala Val Asp Gly Arg Gln Asp Leu Pro Pro Thr
 1 5 10 15
 Pro Ala Ser Phe Cys Ser His Gly Asp Ser Pro Leu Asn Ser Ser Tyr
 20 25 30
 Glu Gln Leu Phe His Leu Tyr Gly Leu Asp Ser Ser Arg Ile Glu Ala
 35 40 45
 Ile Lys Pro Cys Thr Pro Phe Gln Leu Asp Met Ile Asp Cys Asn Ala
 50 55 60

Leu Asp Lys Gln Ser Ala Ile Gly His Ala Val Tyr Asp Val Pro Thr
 65 70 75 80
 Asp Ile Asp Ile Ser Arg Phe Ala Leu Ala Trp Lys Glu Ile Val Asn
 85 90 95
 Gln Thr Pro Ala Leu Arg Ala Phe Ala Phe Thr Ser Asp Ser Gly Lys
 100 105 110
 Thr Ser Gln Val Ile Leu Lys Asp Ser Phe Val Phe Ser Trp Met Cys
 115 120 125
 Trp Ser Ser Ser Ser Ser Pro Asp Glu Val Val Arg Asp Glu Ala Ala
 130 135 140
 Ala Ala Ala Ser Gly Pro Arg Cys Asn Arg Phe Val Leu Leu Glu Asp
 145 150 155 160
 Met Gln Thr Lys Lys Cys Gln Leu Val Trp Thr Phe Ser His Ala Leu
 165 170 175
 Val Asp Val Thr Phe Gln Gln Arg Val Leu Ser Arg Val Phe Ala Ala
 180 185 190
 Tyr Lys His Glu Lys Asp Thr His Arg Pro Glu Thr Pro Glu Ser Ser
 195 200 205
 Asp Ala Thr Asp Thr Asp Ser Gln Ser Val Ser Val Val Ser Met Ser
 210 215 220
 Cys Glu Asp Asn Ala Val Ser Ala Thr His Phe Trp Gln Thr His Leu
 225 230 235 240
 Asn Asp Leu Asn Ala Ser Val Phe Pro His Leu Ser Asp His Leu Met
 245 250 255
 Val Pro Asn Pro Thr Thr Thr Ala Glu His Arg Ile Thr Phe Pro Leu
 260 265 270
 Ser Gln Lys Ala Leu Ser Asn Ser Ala Ile Cys Arg Thr Ala Leu Ser
 275 280 285
 Ile Leu Leu Ser Arg Tyr Thr His Ser Asp Glu Ala Leu Phe Gly Ala
 290 295 300
 Val Thr Glu Gln Ser Leu Pro Phe Asp Lys His Tyr Leu Ala Asp Gly
 305 310 315 320
 Thr Tyr Gln Thr Val Ala Pro Leu Arg Val His Cys Gln Ser Asn Leu
 325 330 335
 Arg Ala Ser Asp Val Met Asp Ala Ile Ser Ser Tyr Asp Asp Arg Leu
 340 345 350
 Gly His Leu Ala Pro Phe Gly Leu Arg Asp Ile Arg Asn Thr Gly Asp
 355 360 365
 Asn Gly Ser Ala Ala Cys Asp Phe Gln Thr Val Leu Leu Val Thr Asp
 370 375 380
 Gly Ser His Val Asn Asn Gly Ile Asn Gly Phe Leu Gln Gln Ile Thr
 385 390 395 400
 Glu Ser Ser His Phe Met Pro Cys Asn Asn Arg Ala Leu Leu Leu His
 405 410 415
 Cys Gln Met Glu Ser Ser Gly Ala Leu Leu Val Ala Tyr Tyr Asp His
 420 425 430
 Asn Val Ile Asp Ser Leu Gln Thr Thr Arg Leu Leu Gln Gln Phe Gly
 435 440 445
 His Leu Ile Lys Cys Leu Gln Ser Pro Leu Asp Leu Ser Ser Met Ala
 450 455 460
 Glu Val Asn Leu Met Thr Glu Tyr Asp Arg Ala Glu Ile Glu Ser Trp
 465 470 475 480
 Asn Ser Gln Pro Leu Glu Val Gln Asp Thr Leu Ile His His Glu Met
 485 490 495
 Leu Lys Ala Val Ser His Ser Pro Thr Lys Thr Ala Ile Gln Ala Trp
 500 505 510
 Asp Gly Asp Trp Thr Tyr Ser Glu Leu Asp Asn Val Ser Ser Arg Leu
 515 520 525

Ala Val His Ile Lys Ser Leu Gly Leu Arg Ala Gln Gln Ala Ile Ile
 530 535 540
 Pro Val Tyr Phe Glu Lys Ser Lys Trp Val Ile Ala Ser Met Leu Ala
 545 550 555 560
 Val Leu Lys Ser Gly Asn Ala Phe Thr Leu Ile Asp Pro Asn Asp Pro
 565 570 575
 Pro Ala Arg Thr Ala Gln Val Val Thr Gln Thr Arg Ala Thr Val Ala
 580 585 590
 Leu Thr Ser Lys Leu His Arg Glu Thr Val Gln Lys Leu Val Gly Arg
 595 600 605
 Cys Val Val Val Asp Asp Glu Leu Leu Gln Ser Val Ser Ala Ser Asp
 610 615 620
 Asp Phe Ser Ser Leu Thr Lys Ser Gln Asp Leu Ala Tyr Val Ile Phe
 625 630 635 640
 Thr Ser Gly Ser Thr Gly Asp Pro Lys Gly Ile Met Ile Glu His Arg
 645 650 655
 Ala Phe Ser Ser Cys Ala Leu Lys Phe Gly Ala Ser Leu Gly Ile Asn
 660 665 670
 Ser Asp Thr Arg Ala Leu Gln Phe Gly Thr His Ala Phe Gly Ala Cys
 675 680 685
 Leu Leu Glu Ile Met Thr Thr Leu Ile Asn Gly Gly Cys Val Cys Ile
 690 695 700
 Pro Ser Asp Asp Asp Arg Met Asn Ser Ile Pro Ser Phe Ile Asn Arg
 705 710 715 720
 Tyr Asn Val Asn Trp Met Met Ala Thr Pro Ser Tyr Met Gly Thr Phe
 725 730 735
 Ser Pro Glu Asp Val Pro Gly Leu Ala Thr Leu Val Leu Val Gly Glu
 740 745 750
 Gln Met Ser Ser Ser Val Asn Ala Ile Trp Ala Pro Lys Leu Gln Leu
 755 760 765
 Leu Asn Gly Tyr Gly Gln Ser Glu Ser Ser Ser Ile Cys Phe Ala Ser
 770 775 780
 Asn Met Ser Thr Glu Pro Asn Asn Met Gly Arg Ala Val Gly Ala His
 785 790 795 800
 Ser Trp Val Ile Asp Pro Asn Asp Ile Asn Arg Leu Val Pro Ile Gly
 805 810 815
 Ala Val Gly Glu Leu Val Ile Glu Ser Pro Gly Ile Ala Arg Asp Tyr
 820 825 830
 Ile Val Pro Pro Pro Pro Glu Lys Ser Pro Phe Phe Thr Asp Ile Pro
 835 840 845
 Ser Trp Tyr Pro Ala Asn Thr Phe Pro Asp Gly Ala Lys Leu Tyr Arg
 850 855 860
 Thr Gly Asp Leu Ala Arg Tyr Ala Ser Asp Gly Ser Ile Val Cys Leu
 865 870 875 880
 Gly Arg Ile Asp Ser Gln Val Lys Ile Arg Gly Gln Arg Val Glu Leu
 885 890 895
 Gly Ala Ile Glu Thr His Leu Arg Gln Gln Met Pro Asp Asp Leu Thr
 900 905 910
 Ile Val Val Glu Ala Thr Lys Arg Ser Gln Ser Ala Asn Ser Thr Ser
 915 920 925
 Leu Ile Ala Phe Leu Ile Gly Ser Ser Tyr Phe Gly Asn Arg Pro Ser
 930 935 940
 Asp Ala His Ile Leu Asp His Asp Ala Thr Lys Ala Ile Asn Ile Lys
 945 950 955 960
 Leu Glu Gln Val Leu Pro Arg His Ser Ile Pro Ser Phe Tyr Ile Cys
 965 970 975
 Met Leu Glu Leu Pro Arg Thr Ala Thr Gly Lys Ile Asp Arg Arg Arg
 980 985 990

Leu Arg Ile Met Gly Lys Asp Ile Leu Asp Lys Gln Thr Gln Gly Ala
 995 1000 1005
 Ile Val Gln Gln Ala Pro Ala Pro Ile Pro Val Phe Ala Asp Thr Ala
 1010 1015 1020
 Ala Lys Leu His Ser Ile Trp Val Gln Ser Leu Gly Ile Asp Pro Ala
 1025 1030 1035 1040
 Thr Val Asn Val Gly Ala Thr Phe Phe Glu Leu Gly Gly Asn Ser Ile
 1045 1050 1055
 Thr Ala Ile Lys Met Val Asn Met Ala Arg Ser Val Gly Met Asp Leu
 1060 1065 1070
 Lys Val Ser Asn Ile Tyr Gln His Pro Thr Leu Ala Gly Ile Ser Ala
 1075 1080 1085
 Val Val Lys Gly Asp Pro Leu Ser Tyr Thr Leu Ile Pro Lys Ser Thr
 1090 1095 1100
 His Glu Gly Pro Val Glu Gln Ser Tyr Ser Gln Gly Arg Leu Trp Phe
 1105 1110 1115 1120
 Leu Asp Gln Leu Asp Val Gly Ser Leu Trp Tyr Leu Ile Pro Tyr Ala
 1125 1130 1135
 Val Arg Met Arg Gly Pro Val Asn Val Asp Ala Leu Arg Arg Ala Leu
 1140 1145 1150
 Ala Ala Leu Glu Gln Arg His Glu Thr Leu Arg Thr Thr Phe Glu Asp
 1155 1160 1165
 Gln Asp Gly Val Gly Val Gln Ile Val His Glu Lys Leu Ser Glu Glu
 1170 1175 1180
 Met Lys Val Ile Asp Leu Cys Gly Ser Asp Leu Asp Pro Phe Glu Val
 1185 1190 1195 1200
 Leu Asn Gln Glu Gln Thr Thr Pro Phe Asn Leu Ser Ser Glu Ala Gly
 1205 1210 1215
 Trp Arg Ala Thr Leu Leu Arg Leu Gly Glu Asp Asp His Ile Leu Thr
 1220 1225 1230
 Ile Val Met His His Ile Ile Ser Asp Gly Trp Ser Ile Asp Val Leu
 1235 1240 1245
 Arg Arg Asp Leu Asn Gln Leu Tyr Ser Ala Ala Leu Lys Asp Ser Lys
 1250 1255 1260
 Asp Pro Leu Ser Ala Leu Thr Pro Leu Pro Ile Gln Tyr Ser Asp Phe
 1265 1270 1275 1280
 Ala Lys Trp Gln Lys Asp Gln Phe Ile Glu Gln Glu Lys Gln Leu Asn
 1285 1290 1295
 Tyr Trp Lys Lys Gln Leu Lys Asp Ser Ser Pro Ala Lys Ile Pro Thr
 1300 1305 1310
 Asp Phe Ala Arg Pro Ala Leu Leu Ser Gly Asp Ala Gly Cys Val His
 1315 1320 1325
 Val Thr Ile Asp Gly Glu Leu Tyr Gln Ser Leu Arg Ala Phe Cys Asn
 1330 1335 1340
 Glu His Asn Thr Thr Ser Phe Val Val Leu Leu Ala Ala Phe Arg Ala
 1345 1350 1355 1360
 Ala His Tyr Arg Leu Thr Ala Val Glu Asp Ala Val Ile Gly Thr Pro
 1365 1370 1375
 Ile Ala Asn Arg Asn Arg Pro Glu Leu Glu Asp Ile Ile Gly Cys Phe
 1380 1385 1390
 Val Asn Thr Gln Cys Met Arg Ile Asn Ile Asp His His Asp Thr Phe
 1395 1400 1405
 Gly Thr Leu Ile Asn Gln Val Lys Ala Thr Thr Thr Ala Ala Phe Glu
 1410 1415 1420
 Asn Glu Asp Ile Pro Phe Glu Arg Val Val Ser Ala Leu Gln Pro Gly
 1425 1430 1435 1440
 Ser Arg Asp Leu Ser Ser Thr Pro Leu Ala Gln Leu Ile Phe Ala Val
 1445 1450 1455

His Ser Gln Lys Asp Leu Gly Arg Phe Lys Phe Gln Gly Leu Glu Ser
 1460 1465 1470
 Val Pro Val Pro Ser Lys Ala Tyr Thr Arg Phe Asp Met Glu Phe His
 1475 1480 1485
 Leu Phe Gln Glu Thr Asp Ser Leu Lys Gly Ser Val Asn Phe Ala Asp
 1490 1495 1500
 Glu Leu Phe Lys Met Glu Thr Val Glu Asn Val Val Arg Val Phe Phe
 1505 1510 1515 1520
 Glu Ile Leu Arg Asn Gly Leu Gln Ser Ser Arg Thr Pro Val Ser Ile
 1525 1530 1535
 Leu Pro Leu Thr Asp Gly Ile Val Thr Leu Glu Lys Leu Asp Val Leu
 1540 1545 1550
 Asn Val Lys His Val Asp Tyr Pro Arg Glu Ser Ser Leu Ala Asp Val
 1555 1560 1565
 Phe Gln Thr Gln Val Ser Ala Tyr Pro Asp Ser Leu Ala Val Val Asp
 1570 1575 1580
 Ser Ser Cys Arg Leu Thr Tyr Thr Glu Leu Asp Arg Gln Ser Asp Ile
 1585 1590 1595 1600
 Leu Ala Gly Trp Leu Arg Arg Arg Ser Met Pro Ala Glu Thr Leu Val
 1605 1610 1615
 Ala Val Phe Ala Pro Arg Ser Cys Glu Thr Ile Val Ala Phe Phe Gly
 1620 1625 1630
 Val Leu Lys Ala Asn Leu Ala Tyr Leu Pro Leu Asp Val Arg Ser Pro
 1635 1640 1645
 Ser Ala Arg Val Gln Asp Ile Leu Ser Gly Leu Ser Gly Pro Thr Ile
 1650 1655 1660
 Val Leu Ile Gly His Asp Thr Ala Pro Pro Asp Ile Glu Val Thr Asn
 1665 1670 1675 1680
 Val Glu Phe Val Arg Ile Arg Asp Ala Leu Asn Asp Ser Asn Ala Asp
 1685 1690 1695
 Gly Phe Glu Val Ile Glu His Asp Ser Thr Lys Pro Ser Ala Thr Ser
 1700 1705 1710
 Leu Ala Tyr Val Leu Tyr Thr Ser Gly Ser Thr Gly Arg Pro Lys Gly
 1715 1720 1725
 Val Met Ile Glu His Arg Val Ile Ile Arg Thr Val Thr Ser Gly Cys
 1730 1735 1740
 Ile Pro Asn Tyr Pro Ser Glu Thr Arg Met Ala His Met Ala Thr Ile
 1745 1750 1755 1760
 Ala Phe Asp Gly Ala Ser Tyr Glu Ile Tyr Ser Ala Leu Leu Phe Gly
 1765 1770 1775
 Arg Thr Leu Val Cys Val Asp Tyr Met Thr Thr Leu Asp Ala Arg Ala
 1780 1785 1790
 Leu Lys Asp Val Phe Phe Arg Glu His Val Asn Ala Ala Ser His Val
 1795 1800 1805
 Thr Ser Ser Ser Gln Asp Val Pro Leu Arg Val Pro Arg Arg Leu Ser
 1810 1815 1820
 Arg Thr Leu Met Phe Phe Leu Val Val Thr Asp Ser Thr Ala Pro
 1825 1830 1835 1840
 Asp Ala Leu Asp Ala Gln Gly Leu Tyr Gln Gly Val Gln Cys Tyr Asn
 1845 1850 1855
 Gly Tyr Gly Pro Thr Glu Asn Gly Val Met Ser Thr Ile Tyr Pro Ile
 1860 1865 1870
 Asp Ser Thr Glu Ser Phe Ile Asn Gly Val Pro Ile Gly Arg Ala Leu
 1875 1880 1885
 Asn Asn Ser Gly Ala Tyr Val Val Asp Pro Glu Gln Gln Leu Val Gly
 1890 1895 1900
 Ile Gly Val Met Gly Glu Leu Val Val Thr Gly Asp Gly Leu Ala Arg
 1905 1910 1915 1920

Gly Tyr Ser Asp Lys Ala Leu Asp Glu Asn Arg Phe Val His Ile Thr
 1925 1930 1935
 Val Asn Asp Gln Thr Val Lys Ala Tyr Arg Thr Gly Asp Arg Val Arg
 1940 1945 1950
 Tyr Arg Ile Gly Asp Gly Leu Ile Glu Phe Phe Gly Arg Met Asp Thr
 1955 1960 1965
 Gln Phe Lys Ile Arg Gly Asn Arg Ile Glu Ser Ala Glu Ile Glu Ala
 1970 1975 1980
 Ala Leu Leu Arg Asp Ser Ser Val Arg Asp Ala Ala Val Val Leu Gln
 1985 1990 1995 2000
 Gln Asn Glu Asp Gln Ala Pro Glu Ile Leu Gly Phe Val Val Ala Asp
 2005 2010 2015
 His Asp His Ser Glu Asn Asp Lys Gly Gln Ser Ala Asn Gln Val Glu
 2020 2025 2030
 Gly Trp Gln Asp His Phe Glu Ser Gly Met Tyr Ser Asp Ile Gly Glu
 2035 2040 2045
 Ile Asp Pro Ser Thr Ile Gly Ser Asp Phe Lys Gly Trp Thr Ser Met
 2050 2055 2060
 Tyr Asp Gly Ser Gln Ile Asp Phe Asp Glu Met His Glu Trp Leu Gly
 2065 2070 2075 2080
 Glu Thr Thr Arg Thr Leu His Asp Asn Arg Ser Leu Gly Asn Val Leu
 2085 2090 2095
 Glu Ile Gly Thr Gly Ser Gly Met Ile Leu Phe Asn Leu Asp Ser Arg
 2100 2105 2110
 Leu Glu Ser Tyr Val Gly Leu Glu Pro Ser Arg Ser Ala Ala Ala Phe
 2115 2120 2125
 Val Asn Lys Ala Thr Glu Ser Ile Pro Ser Leu Ala Gly Lys Ala Lys
 2130 2135 2140
 Val Gln Val Gly Thr Ala Thr Asp Ile Gly Gln Val Asp Asp Leu His
 2145 2150 2155 2160
 Pro Asp Leu Val Val Leu Asn Ser Val Ile Gln Tyr Phe Pro Ser Ser
 2165 2170 2175
 Glu Tyr Leu Ala Glu Ile Ala Asp Thr Leu Ile His Leu Pro Asn Val
 2180 2185 2190
 Gln Arg Ile Phe Phe Gly Asp Val Arg Ser Gln Ala Thr Asn Glu His
 2195 2200 2205
 Phe Leu Ala Ala Arg Ala Ile His Thr Leu Gly Lys Asn Ala Thr Lys
 2210 2215 2220
 Asp Asp Val Arg Gln Lys Met Ala Glu Leu Glu Asp Met Glu Glu Glu
 2225 2230 2235 2240
 Leu Leu Val Glu Pro Ala Phe Phe Thr Ser Leu Lys Asp Arg Phe Pro
 2245 2250 2255
 Gly Leu Val Glu His Val Glu Ile Leu Pro Lys Asn Met Glu Ala Val
 2260 2265 2270
 Asn Glu Leu Ser Ala Tyr Arg Tyr Ala Ala Val Val His Val Arg Gly
 2275 2280 2285
 Ser Leu Gly Asp Glu Leu Val Leu Pro Val Glu Lys Asp Asp Trp Ile
 2290 2295 2300
 Asp Phe Gln Ala Asn Gln Leu Asn Gln Lys Ser Leu Gly Asp Leu Leu
 2305 2310 2315 2320
 Lys Ser Ser Asp Ala Ala Ile Met Ala Val Ser Lys Ile Pro Phe Glu
 2325 2330 2335
 Ile Thr Ala Phe Glu Arg Gln Val Val Ala Ser Leu Asn Ser Asn Ile
 2340 2345 2350
 Asp Glu Trp Gln Leu Ser Thr Ile Arg Ser Ser Ala Glu Gly Asp Ser
 2355 2360 2365
 Ser Leu Ser Val Pro Asp Ile Phe Arg Ile Ala Gly Glu Ala Gly Phe
 2370 2375 2380

Arg Val Glu Val Ser Ser Ala Arg Gln Trp Ser Gln Asn Gly Ala Leu
 2385 2390 2395 2400
 Asp Ala Val Phe His His Cys Cys Ser Gln Gly Arg Thr Leu Val Asn
 2405 2410 2415
 Phe Pro Thr Asp His His Leu Arg Gly Ser Asp Leu Leu Thr Asn Arg
 2420 2425 2430
 Pro Leu Gln Arg Leu Gln Asn Arg Arg Ile Ala Ile Glu Val Arg Glu
 2435 2440 2445
 Arg Leu Arg Ser Leu Leu Pro Ser Tyr Met Ile Pro Ser Asn Ile Val
 2450 2455 2460
 Val Leu Asp Lys Met Pro Leu Asn Ala Asn Gly Lys Val Asp Arg Lys
 2465 2470 2475 2480
 Glu Leu Ser Arg Arg Ala Lys Val Val Pro Lys Gln Gln Thr Ala Ala
 2485 2490 2495
 Pro Leu Pro Thr Phe Pro Ile Ser Glu Val Glu Val Ile Leu Cys Glu
 2500 2505 2510
 Glu Ala Thr Glu Val Phe Gly Met Lys Val Asp Ile Thr Asp His Phe
 2515 2520 2525
 Phe Asn Leu Gly Gly His Ser Leu Leu Ala Thr Lys Leu Ile Ser Arg
 2530 2535 2540
 Ile Asp Gln Arg Leu Lys Val Arg Ile Thr Val Lys Asp Val Phe Asp
 2545 2550 2555 2560
 His Pro Val Phe Ala Asp Leu Ala Ser Val Ile Arg Gln Gly Leu Gly
 2565 2570 2575
 Leu Gln Gln Pro Val Ser Asp Gly Gln Gly Gln Asp Arg Ser Ala His
 2580 2585 2590
 Met Ala Pro Arg Thr Glu Thr Glu Ala Ile Leu Cys Asp Glu Phe Ala
 2595 2600 2605
 Lys Val Leu Gly Phe Gln Val Gly Ile Thr Asp Asn Phe Phe Asp Leu
 2610 2615 2620
 Gly Gly His Ser Leu Met Ala Thr Lys Leu Ala Val Arg Ile Gly His
 2625 2630 2635 2640
 Arg Leu Asp Thr Thr Val Ser Val Lys Asp Val Phe Asp His Pro Val
 2645 2650 2655
 Leu Phe Gln Leu Ala Ile Ala Leu Asp Asn Leu Val Gln Ser Lys Thr
 2660 2665 2670
 Asn Glu Ile Val Gly Gly Arg Glu Met Ala Glu Tyr Ser Pro Phe Gln
 2675 2680 2685
 Leu Leu Phe Thr Glu Asp Pro Glu Glu Phe Met Ala Ser Glu Ile Lys
 2690 2695 2700
 Pro Gln Leu Glu Leu Gln Glu Ile Ile Gln Asp Ile Tyr Pro Ser Thr
 2705 2710 2715 2720
 Gln Met Gln Lys Ala Phe Leu Phe Asp His Thr Thr Ala Arg Pro Arg
 2725 2730 2735
 Pro Phe Val Pro Phe Tyr Ile Asp Phe Pro Ser Thr Ser Glu Pro Asp
 2740 2745 2750
 Ala Ala Gly Leu Ile Lys Ala Cys Glu Ser Leu Val Asn His Leu Asp
 2755 2760 2765
 Ile Phe Arg Thr Val Phe Ala Glu Ala Ser Gly Glu Leu Tyr Gln Val
 2770 2775 2780
 Val Leu Ser Cys Leu Asp Leu Pro Ile Gln Val Ile Glu Thr Glu Asp
 2785 2790 2795 2800
 Asn Ile Asn Thr Ala Thr Asn Glu Phe Leu Asp Glu Phe Ala Lys Glu
 2805 2810 2815
 Pro Val Arg Leu Gly His Pro Leu Ile Arg Phe Thr Ile Ile Lys Gln
 2820 2825 2830
 Thr Lys Ser Met Arg Val Ile Met Arg Ile Ser His Ala Leu Tyr Asp
 2835 2840 2845

Gly Leu Ser Leu Glu His Val Val Arg Lys Leu His Met Leu Tyr Asn
 2850 2855 2860
 Gly Arg Ser Leu Leu Pro Pro His Gln Phe Ser Arg Tyr Met Gln Tyr
 2865 2870 2875 2880
 Thr Ala Asp Gly Arg Glu Ser Gly His Gly Phe Trp Arg Asp Val Ile
 2885 2890 2895
 Gln Asn Thr Pro Met Thr Ile Leu Ser Asp Asp Thr Val Val Asp Gly
 2900 2905 2910
 Asn Asp Ala Thr Cys Lys Ala Leu His Leu Ser Lys Ile Val Asn Ile
 2915 2920 2925
 Pro Ser Gln Val Leu Arg Gly Ser Ser Asn Ile Ile Thr Gln Ala Thr
 2930 2935 2940
 Val Phe Asn Ala Ala Cys Ala Leu Val Leu Ser Arg Glu Ser Asp Ser
 2945 2950 2955 2960
 Lys Asp Val Val Phe Gly Arg Ile Val Ser Gly Arg Gln Gly Leu Pro
 2965 2970 2975
 Val Glu Tyr Gln Asp Ile Val Gly Pro Cys Thr Asn Ala Val Pro Val
 2980 2985 2990
 Arg Ala His Ile Glu Ser Ser Asp Tyr Asn Gln Leu Leu His Asp Ile
 2995 3000 3005
 Gln Asp Gln Tyr Leu Leu Ser Leu Pro His Glu Thr Ile Gly Phe Ser
 3010 3015 3020
 Asp Leu Lys Arg Asn Cys Thr Asp Trp Pro Glu Ala Ile Thr Asn Phe
 3025 3030 3035 3040
 Ser Cys Cys Ile Thr Tyr His Asn Phe Glu Tyr His Pro Glu Ser Gln
 3045 3050 3055
 Phe Glu Gln Gln Arg Val Glu Met Gly Val Leu Thr Lys Phe Val Asn
 3060 3065 3070
 Ile Glu Met Asp Glu Pro Leu Tyr Asp Leu Ala Ile Ala Gly Glu Val
 3075 3080 3085
 Glu Pro Asp Gly Ala Gly Leu Lys Val Thr Val Ile Ala Lys Thr Gln
 3090 3095 3100
 Leu Phe Gly Arg Lys Arg Val Glu His Leu Leu Glu Glu Val Ser Lys
 3105 3110 3115 3120
 Thr Phe Glu Gly Leu Asn Ser Ser Leu
 3125

<210> 3
 <211> 23
 <212> DNA
 <213> Fusarium

<400> 3
 aattgattcg cttgaaagtc gat

23

<210> 4
 <211> 25
 <212> DNA
 <213> Fusarium

<400> 4
 cttgagagtt acgttggtct tgaac

25